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1.1 General introduction 
Walker-Warburg syndrome (WWS) is the most severe clinical entity in a group of 
disorders that show clinical overlap and share a common pathomechanism. At birth, 
patients show hydrocephalus and other severe defects of the central nervous system, 
eye abnormalities, and profound muscle weakness. Brain imaging reveals a number 
of severe structural malformations, including disruption of the cortical layers and 
absence of gyri (lissencephaly), absence of the corpus callosum, thin brainstem and a 
small cerebellum and sometimes encephalocele. Most of these brain malformations 
are indicative of neuronal migration defects. Elevated creatine kinase (CK) levels in 
the blood point to muscular dystrophy. Most WWS patients die in their first year of 
life due to complications such as respiratory infection. The common 
pathomechanism for WWS and related disorders is a defect in the O-linked 
glycosylation of -dystroglycan. Specific O-mannosyl glycans are crucial for the 
function of dystroglycan and hypoglycosylation results in a loss of binding of 
extracellular ligands, such as laminin- 2. Prior to the work described in this thesis, 
recessive mutations were reported in three genes, FKRP, FKTN, and POMT1, in 
approximately one-fifth of the WWS patients in our research cohort (reviewed in 
Chapter 2). 
The research described in this thesis is focused on the elucidation of other genetic 
factors involved in WWS. Elucidation of these factors is urgently needed to improve 
genetic counseling and DNA-diagnostics for families confronted with this 
devastating syndrome. The identification of causative mutations in new genes may 
also help to unravel the molecular mechanisms of disease for clinically overlapping 
disorders. Finally it provides more insights in the biological processes that are 
required for neuronal migration in brain and eye development, and for muscle 
integrity. 
The next paragraphs of this chapter provide background information on protein 
glycosylation in health and disease, and the approaches taken to WWS disease gene 
identification. 
1.2 Protein glycosylation 
All cells of every species studied so far are covered by carbohydrate structures, 
referred to as glycans (Varki, 2007). Glycans are sugar chains, synthesized and 
covalently linked to proteins and lipids in a process called glycosylation. Well-known 
glycans are those found on blood cells, defining the blood groups A, B, AB, and O 
(Landsteiner, 1931; Yamamoto et al., 1990). Cell-surface glycans were first 
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discovered on rat cells by electron microscopy (Rambourg and Leblond, 1967). Until 
two decades ago, it was assumed that glycans are only found facing away from the 
cytosol on the plasma membrane or on membranes of intracellular organelles or on 
secreted molecules (Varki, 2006). Glycans are remarkably diverse in structure, and 
function in a broad range of biological processes. They mediate signalling, cell-cell 
and host-pathogen interactions, and trafficking of glycoconjugates. In addition, 
glycans have intrinsic functions like modification of protein properties such as 
solubility and stability, and are structurally involved in cell membranes and the 
extracellular matrix (Sharon, 1996; Taylor and Drickamer, 2006). 
Glycosylation mainly occurs in the endoplasmic reticulum (ER) and Golgi 
compartments, also referred to as the secretory pathway. An exception to this are 
single O-linked N-acetylglucosamine modifications of proteins in cytosolic and 
nuclear compartments that have regulatory functions, often competing with other 
protein modifications such as phosphorylation (Hart et al., 2007). Protein 
glycosylation occurs at a nitrogen atom (N-linked) of an asparagine residue, or at an 
oxygen atom (O-linked) of serine and threonine residues (Schachter, 2000; Yan and 
Lennarz, 2005). Less common types of glycosylation of specific proteins occurs on 
lysine, tyrosine, and tryptophan residues (Ohtsubo and Marth, 2006). N-linked 
glycosylation is a highly ordered process characterized by a standard repertoire of 
sequential additions and removals of sugar groups. The N-linked glycosylation 
pathway has been resolved in great detail and can be divided into three stages: 
1) formation of a lipid-linked precursor oligosaccharide; 2) en bloc transfer of the 
oligosaccharide to the polypeptide; 3) processing of the oligosaccharide. The first 
two steps and initial trimming reactions (removal of some of the original sugar 
residues) occur in the ER. Further processing takes place as the nascent glycoprotein 
migrates through the Golgi apparatus (Marquardt and Denecke, 2003). N-linked 
glycans have a common protein-glycan linkage and core structure, resulting in a 
relative limited number of different glycan structures. In contrast, O-linked 
glycosylation produces many different glycans structures with eight different 
protein-glycan linkages (Figure 1). 
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Figure 1. Different types of N-, and O-linked glycosylation. N-linked glycans are attached to an 
asparagine residue and have a common core structure (shaded), resulting in a relatively limited number 
of different N-glycan structures. O-linked glycans are attached to serine, threonine or lysine residues. 
Residues at the reducing end of O-glycans (R) are often modified, resulting in many different glycan 
structures. 
Glycosyltransferases in O-linked glycosylation are analogous to those in the N-linked 
biosynthetic pathway, however, there is no precursor oligosaccharide nor en bloc 
transfer of oligosaccharides onto the protein substrate. Glycans are added as 
monosaccharides from nucleotide sugar donors mainly in the Golgi compartments, 
which has parallels with the terminal modification during processing of N-linked 
glycans. Another difference is the apparent lack of a consensus target sequence for 
O-linked glycosylation analogous to the Asn-Xaa-Ser/Thr sequences that define 
N-linked glycosylation sites. Numerous glycosyltransferases can attach GalNAc to 
serine and threonine residues, however, they have specificity for different amino 
acid sequences surrounding the glycosylation target (Taylor and Drickamer, 2006). 
Although glycosaminoglycans (GAGs, or proteoglycans) are also O-linked, these 
glycans are linear, and often highly sulfated and produced by different biosynthetic 
pathways (Esko and Selleck, 2002). The importance of glycosylation in post-
translational protein modification and lipid metabolism is reflected by the 
involvement of a high number of genes, approximately 1% of the mammalian 
transcriptome, that encode glycosylation functions (Lowe and Marth, 2003). Unlike 
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DNA, RNA, and protein synthesis, the biosyntheses of glycans is not template driven 
and subject to multiple sequential and competitive enzymatic pathways (Esko and 
Selleck, 2002; Kornfeld and Kornfeld, 1985; Maccioni et al., 2002; Schachter, 2000). 
The array of glycan structures present on a surface of a specific cell depends on many 
factors involved in cellular regulation of glycan expression, and therefore is difficult 
to predict. Glycan expression is regulated by multiple mechanisms that alter the 
expression and activity of glycosyltransferases and glycosidases, which catalyze the 
synthesis and hydrolysis of glycan structures, respectively. These mechanisms 
include glycosyltransferase and glycosidase gene transcription, synthesis and 
transport of nucleotide sugar donors to the ER and Golgi, modulation of enzymatic 
activity through phosphorylation, substrate competition, intracellular enzyme 
trafficking, and glycan turnover at the cell surface by endocytosis (Ohtsubo and 
Marth, 2006). 
Given the complexity of processes involved in glycosylation and the participation of 
glycans in many key biological processes, it is not surprising that genetic defects in 
glycan biosynthesis underlie the cellular mechanisms of many diseases. 
1.3 Glycosylation defects and disease 
In the past decade, about 40 genetic defects in the glycosylation pathways have been 
reported in the literature that result in a broad range of clinical phenotypes affecting 
nearly all organ systems. Most glycosylation disorders known to date affect N- or 
O-linked protein glycosylation. Almost invariably, genetic glycosylation disorders 
follow a recessive inheritance pattern, indicating that the remaining normal gene 
product in heterozygotes is sufficient to sustain normal physiological processes. 
Glycosylation in cellular mechanisms of health and disease was recently 
comprehensively reviewed (Freeze, 2006; Ohtsubo and Marth, 2006; Wopereis et 
al., 2006). 
In general, genetic disorders that affect the N-linked glycosylation pathway are 
referred to as congenital disorders of glycosylation (CDG). Over 20 different 
autosomal recessive CDGs with a known genetic defect have been reported 
(Foulquier et al., 2007; Freeze, 2006; Kranz et al., 2007a; Kranz et al., 2007b). The 
CDGs are grouped in CDG type I and type II, and subtypes that are caused by 
mutations in different genes are indicated by lower case letters; CDG-Ia – CDG-Im, 
and CDG-IIa – CDG-IIh. Type I CDGs are caused by defects in the synthesis of the 
lipid-linked oligosaccharide precursor in the endoplasmic reticulum, which results 
in inefficient and/or incomplete transfer of the oligosaccharide by an 
oligosaccharyltransferase to an asparagine residue. Defects in the further processing 
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of the protein N-linked glycans originate in the Golgi and are referred to as CDG type 
II. 
With exception of CDG-Ia, which is caused by mutations in the PMM2 gene, only few 
patients have been identified for each CDG subtype. The limited number of patients 
and overlapping clinical features make it difficult to clinically define CDG subtypes. 
In general, CDG patients present with neurological and multi-systemic diseases, 
with common symptoms such as psychomotor retardation, seizures, central nervous 
system abnormalities, hypotonia, coagulation defects, and liver disease. More 
specific clinical signs for CDG-I, such as inverted nipples, abnormal fat distribution, 
and hypoplasia of the cerebellum, may guide an early diagnosis. CDG-II patients are 
diagnosed with “classical” CDG features in combination with other unique features 
such as haemorrhages, cutis laxa, and impaired immune system (Wopereis, 2006). 
Unsolved cases of CDG-II (CDG-IIx) present specific clinical symptoms such as 
deafness, blindness, and urogenital anomalies (Wopereis et al., 2005). The diagnosis 
of CDGs is guided by biochemical analysis of glycans. Plasma transferrin is a 
sensitive and commonly used marker that can be investigated by various methods 
including isoelectric focusing, high-performance liquid chromatography, capillary 
electrophoresis, and mass spectrometry. These techniques allow for the detection of 
altered glycosylation and help to focus the search for the defect, however they cannot 
pinpoint the defect. Specific biochemical assays are developed to analyze i.e. enzyme 
activities and glycosylation intermediates. Particularly the first steps in N-linked 
glycosylation are highly conserved in evolution and comparison of lipid-linked 
oligosaccharide structures of  yeast mutant strains with those of CDG type I patients 
resulted in the elucidation of genetic defect of various CDG type I disorders 
(Wopereis et al., 2005). Only few mouse models exist for human CDG genes. Null-
alleles for most mouse orthologs of the CDG genes are not compatible with life in 
mice. Likewise, human null alleles are also not compatible with life as most patients 
with a CDG carry hypomorphic alleles rather than complete loss-of-function alleles 
(Freeze, 2006). 
An emerging new group of CDG-II defects is characterized by defects in trafficking of 
multiple glycosyltransferases and in nucleotide-sugar transporters, which affect 
multiple glycosylation pathways. CDG-IIe is the first disorder where mutations in a 
subunit of the conserved oligomeric Golgi (COG) complex, COG7, were described 
that disrupt Golgi trafficking, resulting in abnormal N-, and O-linked glycosylation 
(Wu et al., 2004). Mutations in two other COG subunits were recently identified, 
COG1 in CDG-IIg, and COG8 in CDG-IIh (Foulquier et al., 2006; Foulquier et al., 
2007; Kranz et al., 2007b). These findings indicate that disruption intra-Golgi 
trafficking of protein complexes may account for other types of glycosylation 
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disorders with combined defects in N- and O-linked protein glycosylation. This was 
demonstrated by the recent identification of loss-of-function mutations in the a2 
subunit of the V-type H+ -ATPase in several families with syndromal cutis laxa and 
CDG-II, which also cause an impairment of Golgi trafficking probably due to 
disruption of local pH gradients  (Kornak et al., 2008). 
Most disorders caused by abnormal O-linked glycosylation are not included in the 
CDG nomenclature. They comprise a larger group of patients with a highly variable 
clinical presentation. Wopereis et al., comprehensively reviewed the O-glycan 
biosynthesis and the clinical and molecular aspects of defects in this process 
(Wopereis et al., 2006). The variable composition, linkage, and branching of 
O-glycans makes the detection of defects in O-glycan biosynthesis more complex 
than for N-glycan defects. Recently, an isoelectric focusing assay of a plasma protein, 
apolipoprotein C-III (ApoCIII), has been developed to screen for defects in 
biosynthesis of a mucin-type O-glycan found on many secreted proteins (Wopereis et 
al., 2003). However, most congenital defects of O-linked glycosylation have been 
identified by genetic studies. Table 1 lists currently known disorders of O-linked 
glycosylation. 
A distinct group of disorders is caused by defects in the synthesis of O-linked 
mannose glycans for which the only known target is -dystroglycan. Defects in the 
synthesis of these glycans can be detected by immunohistochemical staining of 
-dystroglycan on muscle biopsies with monoclonal antibodies VIA4-1 and IIH6 
(Michele et al., 2002). It is not clear which carbohydrate epitope is recognized by the 
antibodies, and abnormal staining may occur also for defects in N-glycan or mucin-
type O-glycan biosynthesis (Huizing et al., 2004; Wopereis et al., 2006). Defects in 
the O-linked mannose glycosylation of -dystroglycan cause a disease spectrum of 
congenital muscular dystrophy (CMD) syndromes (Table 1), including structural 
brain and eye abnormalities in severe cases. These CMDs are denoted merosin-
positive, because patients have no immunohistochemical abnormalities in 
laminin- 2 (merosin), which is seen in common forms of CMD, the laminopathies. 
It recently became evident that different mutations in all known genes involved in 
these disorders give rise to clinical variability, and to an overlap in clinical features 
of these disorders. Chapter 2 reviews the clinical characteristics, molecular genetics, 
and disease mechanisms of the most severe disorders in this clinical spectrum, 
Walker-Warburg syndrome and related disorders, as known in mid-2004.  Disorders 
with disrupted O-mannose glycosylation are extremely rare and show a pattern of 
recessive inheritance. The incidence of these disorders, as for other rare autosomal 
recessive conditions, is higher in populations with a high rate of consanguineous 
unions. This phenomenon may be exploited to identify candidate disease loci. 
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Table 1. Human disorders of O-linked glycosylation 
Disorder OMIM Gene 
O-Gal   
Ehlers-Danlos syndrome type VI 225400 PLOD 
O-GalNAc   
Familial Tumoral Calcinosis 211900 GALNT3 
Tn syndrome 230430 COSMC 
O-glycan sialylation   
Congenital disorder of glycosylation type IIf 603585 SLC35A1 
Distal myopathy with rimmed vacuoles 605820 GNE 
Inclusion body myopathy 2 600737 GNE 
Sialuria 269921 GNE 
O-Man   
Congenital muscular dystrophy, no MR 607155 FKRP, FKTN 
Congenital muscular dystrophy + MR 606612 FKRP, POMT1 
Congenital muscular dystrophy + CRB 608840 FKRP, LARGE, POMT1, POMT2  
Fukuyama congenital muscular dystrophy 253800 FKTN 
Limb-girdle muscular dystrophy+ MR  609308 POMT1, POMT2 
Limb-girdle muscular dystrophy, no MR 607155 FKRP, FKTN, POMGnT1, POMT2 
Muscle-eye-brain disease 253280 POMGnT1 
Muscle-eye-brain disease like  FKRP, POMT1, POMT2 
Walker-Warburg syndrome 236670 POMT1, POMT2, FKTN, FKRP, 
LARGE 
O-Xyl   
Multiple hereditary exotosis 133700, 133701, 
600209 
EXT1, EXT2, EXT3 
Progeroid variant of Ehlers-Danlos syndrome 130070 B4GALT7 
O-Xyl sulfation   
Chondrodysplasias 600972, 222600, 
256050 
DTDST 
Macular Corneal Dystrophy 217800 CHST6 
Multiple Epiphyseal Dysplasia 226900 DTDST 
Spondyloepiphyseal dysplasia 608637, 603005 CHST3, ATPSK2 
N-, and O-glycan   
Congenital disorder of glycosylation type IIc 266265 FUCT1 
Congenital disorder of glycosylation type IId 607091 B4GALT1 
Congenital disorder of glycosylation type IIe 608779 COG7 
Congenital disorder of glycosylation type IIg 611209 COG1 
Congenital disorder of glycosylation type IIh 611182 COG8 
Cutis laxa, autosomal recessive, type II 219200 ATP6V0A2 
Wrinkly skin syndrome 278250 ATP6V0A2 
Anderson disease 607689 SARA2 
Chylomicron retention disease 246700 SARA2 
Chylomicron retention disease with Marinesco-Sjogren 
syndrome 
607692 SARA2 
Bombay blood group 211100 FUT1, FUT2 
Para-Bombay blood group 211100 FUT1 
Non-secretor blood group 182100 FUT2 
Lewis-negative blood group 111100 FUT3 
MR, mental retardation; CRB, cerebellar involvement 
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1.4 Disease-locus identification in autosomal recessive 
disorders 
It was noted as early as 1902 that an unusually high number of patients with 
alkaptonuria were born to consanguineous parents (Garrod, 1902). The Mendelian 
explanation for this phenomenon was given soon after, and it was also predicted and 
observed that the rarer a disease the more pronounced this phenomenon (Lander 
and Botstein, 1987). A consanguineous marriage is most commonly defined as a 
union between a couple related as second cousins or closer. In theory, first-cousins 
share 1/8 of all their alleles, and seconds-cousins share 1/32 of all their alleles. 
Descendants of consanguineous parents inherit half of these common alleles 
(Figure 2). The assembly of two rare disease alleles is therefore more frequently 
observed in descendants from consanguineous parents compared to descendants 
from unrelated parents. 
 
 
Figure 2. Example of a family pedigree 
showing a first-cousin relationship between 
individuals III-1 and III-2, represented by a 
double line (consanguinity). Half of the 
genome between individuals II-2 and II-3, 
and IV-1 and IV-2 is identical by descent. 
Individuals III-1 and III-2 share 1/8 of their 
genome.  Half of their shared genome (1/16) 
is inherited by their children which is 
identical by descent (homozygous). Females 
are represented by circles, males by squares. 
Open symbols represent the unaffected 
family members, the solid black symbols the 
affected sibling. 
 
 
In 1953, Cedric Smith noted the theoretical efficiency of studying inbred affected 
children, given a tightly linked highly polymorphic marker. The paucity of such 
highly polymorphic markers and the inability at that time to construct complete 
linkage maps of less polymorphic markers led Smith to conclude that "the method is 
impractical” (Smith, 1953). His theory relied on the fact that a child with a recessive 
disease with consanguineous parents co-inherits a homozygous (also referred to as 
autozygous) region of many centimorgans (cM) surrounding the disease locus. 
Depending on the degree of parental relationship, several regions of homozygosity 
will be present in any child from consanguineous parents, however, these will vary 
between children and only a homozygous disease locus will be “shared” by patients 
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with a genetically homogeneous disorder. Upon completion of a restriction fragment 
length polymorphism (RFLP) linkage map of the human genome in 1987, Eric 
Lander and David Botstein further explored the possibility to detect homozygosity 
by descent in order to map recessive traits in humans. The method should make it 
possible to map rare recessive diseases for which it is impractical or impossible to 
collect adequate numbers of families with multiple affected offspring. Based on their 
calculations, identification of a disease locus by homozygosity mapping should be 
feasible with few inbred patients when a human genetic map is available with a 
marker spacing of 10 cM, and with markers that are homozygous in at most half of 
the population (Lander and Botstein, 1987). The first successful applications of 
homozygosity mapping were in 1992, when the genetic defects were mapped for 
Werner syndrome to 8p, for familial Mediterranean fever to 16p, and Tunisian 
autosomal Duchenne-like muscular dystrophy to 13q (Ben Othmane et al., 1992; 
Goto et al., 1992; Pras et al., 1992). Homozygosity mapping is limited by the 
availability of affected offspring of related parents, however, geographical isolation 
and cultural norms resulted in populations where consanguinity is widespread. 
Contrary to what many people from western countries assume, consanguinity is not 
restricted to populations which are geographically or religiously isolated, instead, 
consanguineous marriages are favoured in many populations. In some populations 
the rate of consanguineous marriages exceeds 50% (Figure 3) (Bittles, 2001). 
Calculations predict that 6% (1/16) of the genome of a child of first cousins will be 
homozygous with on average homozygous segments of 20 cM. However, a study that 
quantified homozygosity in populations that have preferred consanguineous 
marriage for many generations showed that children of first-cousin parents have an 
overall homozygosity of approximately 11% (range 5-20, n=38), with on average a 
disease causing homozygous segment of 26 cM (range 5-70, n=100). This raise in 
overall homozygosity increases the chance of finding false linkage for a disease locus 
in small families, and shows that calculations based on pedigrees may underestimate 
the percentage of homozygosity (Woods et al., 2006). 
Until four years ago, the standard method for identifying disease loci involved a 
whole-genome scan using a set of 300-400 highly informative multi-allelic 
microsatellite markers equally spaced across the genome. However, the enormous 
progress in detection and genotyping of single-nucleotide polymorphisms (SNPs) 
resulted in a growing popularity of using SNP markers. To date, more than 6.5 
million human SNPs have been identified (validated SNPs, NCBI dbSNP Build 129) 
by large sequencing efforts like the HapMap project (http://www.hapmap.org). 
Despite a lower information content of the mostly biallelic SNP-markers (Kennedy et 
al., 2003), the rapid and highly automated genotyping of SNPs allows for high-
throughput screening of nearly one million SNP-markers (Genome-wide SNP array 
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6.0, Affymetrix) at the time of writing this thesis. Several studies have compared 
whole-genome scan data from SNP-markers (>10K SNPs) with traditional 10-cM 
microsatellite marker set (~400 Simple Tandem Repeat markers), and showed the 
two major advantages of using the high-density SNP-scan over microsatellites; 
higher overall information content resulting in a better definition of linkage peaks, 
and speed of genotyping and downstream data processing (John et al., 2004; 
Middleton et al., 2004). In addition, these more dense arrays also allow for copy 
number detection by which small deletions and duplications can be mapped. 
 
 
Figure 3. World-wide prevalence of consanguinity (www.consang.net, reprinted with permission of A.H. 
Bittles) 
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1.5 Positional candidate disease gene selection 
For genetically heterogeneous and severe disorders, such as WWS, a candidate 
disease locus can be several megabases in size, often containing 50 or more genes. 
Comprehensive analysis of so many candidate genes is very time-consuming and 
expensive. Public availability of data derived from various genome-sequencing 
projects, and large-scale “omic” studies, resulted in a wealth of biological 
information, stored in many different databases (Kanehisa and Bork, 2003; Stein, 
2003). To facilitate retrieval of such information from frequently used databases, 
retrieval systems have been developed, such as Entrez, MRS, and SRS (Table 2). 
Genome browsers, such as the University of California, Santa Cruz (UCSC) Genome 
Browser, and Ensembl (Table 2), integrated data from various sources with 
positional information making these browsers indispensable for users who study 
genes based on genomic context and in relation to their biological function or 
malfunction resulting in disease. Both, the UCSC, and Ensembl genome browsers 
provide a tool, Gene Sorter and BioMart, respectively, for step-by-step data filtering, 
based on genomic position, gene expression, gene ontology, and many other criteria. 
Many computational methods have been developed for bioinformatics analysis of a 
candidate disease locus to select the most likely candidate disease genes. Various 
tools have been developed to assist these researchers in systematic prioritization of 
candidate genes. Table 2 lists a selection of tools, which are commonly used for 
candidate disease gene prediction or prioritization. Recent papers discuss the 
differences in methodology for different tools, and the application of a concert of 
methods to prioritize candidate genes (Oti and Brunner, 2007; Tiffin et al., 2006; 
van Driel and Brunner, 2006). 
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Table 2. Tools for retrieval of biological data, candidate disease gene prediction or prioritization 
Name Description URL or reference 
Data retrieval tools 
Entrez NCBI‟s life sciences cross-database search tool http://www.ncbi.nlm.nih.gov/Entrez 
MRS Cross-database search tool http://mrs.cmbi.ru.nl 
SRS Cross-database search tool including data 
analysis tools 
http://srs.bioinformatics.nl 
 
Human genome browsers 
Ensembl Annotated assembly of the complete human 
genome 
http://www.ensembl.org/Homo_sapiens 
UCSC Genome 
browser 
Annotated assembly of the complete human 
genome 
http://genome.ucsc.edu/cgi-
bin/hgGateway?org=Human 
 
Disease gene prediction  
Disease gene 
prediction (DGP) 
Based on protein sequence properties and 
evolutionary conservation of known disease 
proteins 
http://cgg.ebi.ac.uk/services/dgp 
Protein–protein 
interactions 
List of 300 candidate disease gene predictions 
based on protein-protein interactions 
no web tool (Oti et al., 2006) 
   
Gene prioritization 
Endeavour Prioritization of positional candidate disease 
genes based on sequence, gene expression, 
functional annotation, pathways, and 
literature mining 
http://www.esat.kuleuven.be/endeavour 
Genes2Diseases 
(G2D) 
Prioritization of positional candidate disease 
genes based on sequence, functional 
annotation, and literature mining 
http://www.ogic.ca/projects/g2d_2 
GeneSeeker Filters positional candidate disease genes 
based on expression and phenotypic data 
from human and mouse 
http://www.cmbi.ru.nl/GeneSeeker 
Oti et al., 2008 Conserved co-expression for candidate disease 
gene prioritization 
http://www.cmbi.ru.nl/~moti/coexpression/ 
POCUS  Selection of candidate disease genes based on 
shared functional annotation, InterPro 
domains, and expression profiles with two or 
more known disease genes 
no web tool (Turner et al., 2003) 
Prioritizer  Prioritization of positional candidate disease 
genes based on sequence, gene expression, 
functional annotation, pathways, and 
literature mining 
http://www.prioritizer.nl 
SUSPECTS Prioritization of positional candidate disease 
genes based on gene and protein sequence 
properties, functional annotation, and gene 
expression 
http://www.genetics.med.ed.ac.uk/suspects 
Tiffen et al. Prioritization of candidate disease genes 
based on literature mining and expression 
no web tool (Tiffin et al., 2005) 
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1.6 Outline of this thesis 
Work described in this thesis covers the elucidation of the genetic basis of WWS and 
related disorders. Chapter 2 reviews the clinical characteristics, and genetics of 
WWS known at the start of my research project in 2004. Chapters 3 and 4 
describe the identification of two new WWS genes. Small gene mutations were 
identified in POMT2 in four WWS patients from three unrelated families. 
Furthermore a 63-kb intragenic deletion in the LARGE gene was found in one WWS 
family. Chapters 5 and 6 describe the phenotypic differences observed for 
different mutations in POMT1 and FKRP. Seven new POMT1 mutations were 
identified in patients with a less severe phenotype compared to WWS consisting of 
mental retardation, CMD and calf hypertrophy. In addition, seven new POMT1 
mutations are reported in WWS patients. A case reports describes a WWS family 
with homozygous FKRP startcodon mutations. A final discussion and prospects on 
the glyc-O-genetics of WWS and related disorders is given in Chapter 7. 
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Abstract 
Walker-Warburg syndrome is the most severe of a group of multiple congenital 
anomaly disorders known as the cobblestone lissencephalies. These are 
characterized by congenital muscular dystrophy in conjunction with severe brain 
malformation and ocular abnormalities. In the last 3 years, important progress has 
been made towards the elucidation of the genetic causes of these disorders. 
Mutations in three genes, POMT1, fukutin and FKRP, have been described for 
Walker-Warburg syndrome, which together account for approximately 20% of 
patients with Walker-Warburg syndrome. It has become evident that some of the 
underlying genes may cause a broad spectrum of phenotypes, ranging from 
limb-girdle muscular dystrophy type 2I to Walker-Warburg syndrome. In some 
cases, a genotype-phenotype correlation can be recognized. In line with the known 
or proposed functions of the resolved genes, all patients with cobblestone 
lissencephaly show defects in the O-linked glycosylation of the glycoprotein 
-dystroglycan. Perhaps, the missing genes underlying the remainder of the 
unexplained Walker-Warburg syndrome patients have also to be sought in the 
pathways involved in O-linked protein glycosylation. 
Introduction 
Walker-Warburg syndrome (WWS; MIM236670) was named after Walker, who 
reported the first patient with lissencephaly (smooth brain) in 1942 (Walker, 1942), 
and after Warburg who proposed its autosomal recessive inheritance (Warburg, 
1976; Warburg, 1978). Patients with this rare developmental disorder have a life 
expectancy of less than 3 years (average 0.8 years). Numerous congenital anomalies 
have been reported, but the most consistent are malformations of three structures: 
muscle, eye and brain. This triad distribution of developmental defects is also found 
in muscle-eye-brain disease (MEB; MIM 253280) and Fukuyama congenital 
muscular dystrophy (FCMD; MIM 253800), which together with WWS comprise the 
group of the cobblestone lissencephalies. The clinical features of WWS are most 
severe, especially with regard to the brain phenotype, which may be diagnosed 
prenatally (Dobyns et al., 1989). Typical brain anomalies include hydrocephalus, 
neuronal overmigration, causing a cobblestone cortex, lissencephaly, agenesis of the 
corpus callosum, fusion of the hemispheres, dilatation of the fourth ventricle, 
cerebellar hypoplasia and occasionally occipital encephalocele (Figure 1) (Cormand 
et al., 2001).  
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Figure 1. Phenotypes of 
Warburg syndrome (WWS), 
muscle-eye-brain disease 
(MEB) and Fukuyama 
congenital muscular 
dystrophy (FCMD). Please 
note that the severity of the 
shared characteristics may 
vary among the three 
syndromes, usually from 
severe in WWS to moderate 
and less severe in MEB and 
FCMD patients. 
 
In addition to the brain phenotype, patients can have a number of congenital ocular 
abnormalities, such as cataract, microphthalmia, buphthalmus, persistent 
hyperplastic primary vitreous and Peters anomaly. WWS patients have little motor 
activity due to the severe congenital muscular dystrophy (Dobyns et al., 1989; 
Warburg, 1976; Warburg, 1978). Serum creatine kinase levels are usually well above 
1000 U/l. Differentiation between WWS, MEB, and FCMD can be made by 
examination of the brain architecture using imaging techniques like MRI and CT-
scanning or by post-mortem examination (Figure 1). The structural eye defects in 
FCMD patients are generally mild if present at all, which distinguishes these patients 
from WWS and MEB patients (Cormand et al., 2001; Yoshioka and Kuroki, 1994). 
On the basis of familial co-occurrence, it was initially suggested that WWS and 
FCMD are allelic disorders (Toda et al., 1995), but subsequent genetic analyses 
contradicted that hypothesis (Cormand et al., 2001). It was demonstrated that the 
three types of cobblestone lissencephaly have a different genetic causation, because a 
number of WWS families did not map to the known loci for FCMD at 9q31 and MEB 
at 1p34-p33 (Cormand et al., 1999; Toda et al., 1993). Ironically, now that we know 
more about the causative genes for cobblestone lissencephaly, it becomes evident 
that allelism between these three syndromes does occur, albeit rarely. 
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WWS genetics 
It is typical for rare autosomal recessive disorders that most cases originate from 
populations with a high consanguinity rate. One clear conclusion from attempts at 
homozygosity mapping for WWS is that the disease is genetically heterogeneous 
(Beltrán-Valero de Bernabé et al., 2002). This suggests that WWS is the result of 
malfunctioning of a molecular complex or pathway and not of a single gene 
disruption. The heterogeneity has precluded the identification of WWS genes by a 
positional cloning strategy. For this reason, a functional candidate gene approach 
combined with directed linkage mapping seems to be the only good alternative to 
identify one or more genes underlying WWS. Clinical similarity with MEB, and the 
notion that the POMGnT1 gene encodes a glycosylation enzyme, led to the 
identification of the first causative gene in WWS (Beltrán-Valero de Bernabé et al., 
2002), the POMT1 gene on chromosome 9q34. Mutations in this gene account for 
6/30 WWS patients (20%). Further evidence for genetic heterogeneity in WWS came 
with the identification of mutations in two other genes. Homozygous nonsense 
mutations were identified in the fukutin gene in two unrelated Turkish families 
(Beltrán-Valero de Bernabé et al., 2003; Silan et al., 2003). The fukutin gene was 
tested in these families, because it is the causative gene in FCMD. The vast majority 
of FCMD patients are homozygous for a mild founder mutation in the Japanese 
population that arose about 3000 years ago (Colombo et al., 2000; Kobayashi et al., 
1998). In contrast, the WWS fukutin mutations appear to be more severe. Fukutin 
mutations probably contribute very little to the prevalence of WWS. In our series, 
only three of 30 consanguineous WWS families mapped to this locus and a fukutin 
mutation was identified in only one of them (Beltrán-Valero de Bernabé et al., 
2003). The third known WWS gene is FKRP, which encodes the fukutin-related 
protein. Mutations in FKRP have also been detected in a number of congenital 
muscular dystrophies with variable severity (Brockington et al., 2001a; Brockington 
et al., 2001b; Topaloglu et al., 2003). The clinical spectrum associated with FKRP 
mutations was broadened by the identification of a homozygous missense mutation 
in a WWS patient of Pakistani origin (Beltrán-Valero de Bernabé et al., 2004). The 
patient presented typical WWS features and was previously included in a clinical 
review of MEB and WWS by Cormand et al. (Cormand et al., 2001). Again, 
mutations in the FKRP gene account for only a marginal number of WWS patients as 
only two of 29 consanguineous patients in our series showed homozygosity at the 
FKRP locus and mutations were found in only one of those two (Beltrán-Valero de 
Bernabé et al., 2004). 
In our experience, causative mutations in the three known WWS genes are found in 
eight of 40 (20%) patients (Beltrán-Valero de Bernabé et al., 2002; Beltrán-Valero 
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de Bernabé et al., 2003; Beltrán-Valero de Bernabé et al., 2004) (van Reeuwijk, 
unpublished data). Genome-wide linkage studies in the unexplained families are still 
in progress, and the number of remaining loci remains unclear. Given the lack of 
overlapping linkage intervals between individual families, it is entirely possible that 
three or more genes remain to be identified in WWS (van Reeuwijk, unpublished 
data). 
WWS and related disorders: is there a genotype-
phenotype correlation? 
The clinical spectrum arising from mutations in genes involved in cobblestone 
lissencephaly is much wider than previously envisaged. There are several factors that 
may account for this: (i) the function or step in O-linked glycosylation that is 
catalyzed by the corresponding protein; (ii) the presence of complementing genes; 
(iii) the severity of the mutation. Information about the first two possibilities is 
provided in the next section; in this paragraph, we elaborate on the third possibility 
by providing some examples of a genotype-phenotype correlation. 
The clearest genotype-phenotype correlations are seen for fukutin gene mutations. 
The Japanese founder mutation is a 3-kb retrotransposon insertion in the 3‟UTR, 
which results in reduced levels of fukutin mRNA, yet with the capacity to produce a 
normal protein (Kondo-Iida et al., 1999). Patients who are homozygous for this 
retrotransposon mutation have the typical FCMD phenotype. The phenotype is 
significantly more severe in compound heterozygotes carrying the insertion in 
combination with a nonsense or missense mutation in the other allele (Kobayashi et 
al., 1998; Kondo-Iida et al., 1999; Saito et al., 2000). WWS is at the most severe end 
of the phenotypic spectrum and is caused by homozygous nonsense mutations in the 
fukutin gene (Beltrán-Valero de Bernabé et al., 2003; Silan et al., 2003). 
A much wider phenotypic spectrum is observed for mutations in the FKRP gene 
(Figure 2). Mutations in FKRP were first described by Brockington and coworkers 
in patients with a severe form of congenital muscular dystrophy, denoted MDC1C 
(Brockington et al., 2001a), and in the much milder limb girdle muscular dystrophy 
type 2I (LGMD2I) (Brockington et al., 2001b). The clinical manifestation of the 
muscular dystrophy in LGMD2I patients is quite variable, and homozygous carriers 
of FKRP mutations can be asymptomatic at older age (de Paula et al., 2003). Clinical 
variability is also seen at the severe end of the spectrum. A patient was reported with 
severe congenital muscular dystrophy and mental retardation, cerebellar cysts and 
other cerebellar abnormalities (Topaloglu et al., 2003). Subsequently, FKRP 
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mutations were identified in the gradually more severe MEB and WWS phenotypes. 
A genotype-phenotype correlation is not obvious for the FKRP mutations that are 
found in the various disorders. Most of the FKRP mutations create amino acid 
substitutions and their functional consequences are hard to predict owing to a lack 
of knowledge about the function of FKRP protein. In some instances, the effects of 
missense mutations can be inferred from the associated phenotypes. For example, 
the homozygous mutation in FKRP (Tyr307Asn) that was found in an MEB patient 
was previously found in heterozygosity in patients suffering from LGMD2I. The less 
severe mutation in the second allele, Leu276Ile, is a common mutation in patients 
with LGMD2I and often found in homozygosity in them causing a relatively mild 
form of LGMD2I. In contrast, the patient with a compound heterozygous mutation 
of Tyr307Asn and Leu276Ile suffered from quite severe LGMD2I and died in his late 
teens, suggesting that theTyr307Asn mutation is more detrimental for FKRP 
function than is the Leu276Ile (Beltrán-Valero de Bernabé et al., 2004).  
 
 
 
Figure 2. Overview of the genotype–phenotype correlation seen in the cobblestone lissencephalies. The 
mutations in the genes resulting in the different disorders are depicted by + (rare) and ++ (common). 
The Largemyd mouse phenotype resembles a muscle-eye-brain disease (MEB)/Fukuyama congenital 
muscular dystrophy (FCMD) phenotype in humans represented by an asterisk (*). POMGnT1 mutations 
have been found in patients diagnosed as mild Walker-Warburg syndrome (WWS) and severe FCMD, 
because their phenotypic characteristics precluded an unequivocal classification into either of these 
categories. 
The final example of a genotype-phenotype correlation is provided by mutations in 
the POMGnT1 gene. MEB is most prevalent in the Finnish population due to a 
founder mutation in the POMGnT1 gene (de la Chapelle and Wright, 1998). 
Recently, Toda and coworkers reported a much wider clinical spectrum associated 
with POMGnT1 gene mutations, which were identified in patients from all over the 
world. The mutant POMGnT1 phenotype varied from severe FCMD to MEB to a 
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WWS-like phenotype, which was less severe than classical WWS. A slight correlation 
was observed between the clinical severity of the brain phenotype and the location of 
the mutations in this gene. Mutations near the 5‟-terminus of the POMGnT1-coding 
region tend to show more severe brain abnormalities, including hydrocephalus, 
compared to patients with mutations more downstream who do not have 
hydrocephalus (Figure 3). No differences were observed for the skeletal muscle in 
which (in both cases) staining of the -dystroglycan was highly reduced (Taniguchi 
et al., 2003).  
 
 
Figure 3. Schematic representation of the proteins involved in cobblestone lissencephalies and the type and 
position of reported mutations. Compound heterozygosity (ch) is only indicated when associated with an 
intermediate phenotype. Note that the same missense mutation in POMGnT1 (E223K) in combination with a 
truncating mutation at the 5‟ end (F149fs) gives rise to a more severe phenotype than in combination with a 
truncating mutation at the 3‟ end (IVS17+1G>T/A). Protein domains are: PMT, protein mannosyl transferase 
domain; GnT-1, N-acetylglucosaminyltransferase domain; MIR, mannosyltransferase-IP3R-RyR domain; SS, 
signal sequence; TM, transmembrane domain; DxD, Asp, Xaa, Asp motif. 
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As we have seen, mutations in three of the genes involved in cobblestone 
lissencephaly give rise to a wide phenotypic spectrum, with or without a clear 
genotype-phenotype correlation (Figures 2 and 3). We also hypothesize that mild 
mutations in POMT1 might result in the clinically milder disorders such as MEB or 
FCMD. Indeed, there are still several such patients without a mutation in POMGnT1, 
fukutin or FKRP. Clinical variability remains to be explored for mutations in the 
LARGE gene. Compound heterozygous mutations in the human LARGE gene have 
been identified in a single patient with a novel type of congenital muscular dystrophy 
(MDC1D) and severe mental retardation (Longman et al., 2003). Interestingly, the 
Largemyd mouse, which carries an intragenic deletion of exon 4-7 in the LARGE gene, 
has a phenotype that is strikingly similar to the FCMD, MEB and WWS phenotypes 
in humans (Grewal et al., 2001; Michele et al., 2002; Moore et al., 2002). 
Abnormal glycosylation of -dystroglycan is a key 
feature of the cobblestone lissencephalies 
The POMT1 gene was selected as a functional candidate for WWS, because of its 
anticipated role in the post-translational O-linked glycosylation of -dystroglycan 
(Beltrán-Valero de Bernabé et al., 2002). Currently, there is compelling evidence 
that shows that the lack of O-linked glycosylation of -dystroglycan is the key defect 
in WWS and other cobblestone lissencephalies (Endo and Toda, 2003; Grewal and 
Hewitt, 2003; Martin, 2003; Martin and Freeze, 2003; Martin-Rendon and Blake, 
2003; Muntoni et al., 2004). The first line of evidence is genetics. POMT1 is 
predicted to catalyze the first step in the O-linked protein mannosylation, the 
transfer of a mannosyl residue from dolichyl phosphate mannose to a serine or 
threonine residue in the target protein (Jurado et al., 1999; Strahl-Bolsinger et al., 
1999). POMGnT1 takes care of the second step by adding an N-acetylglucosamine 
residue to a pre-existing protein O-linked mannose (Yoshida et al., 2001). The 
-dystroglycan protein is the only known substrate for this type of glycosylation in 
mammals. The second line of evidence is provided by immunohistochemical and 
functional analyses of -dystroglycan in material obtained from patients and animal 
models. There are many reports of strongly reduced or complete lack of glycosylation 
of -dystroglycan in material from patients with WWS, MEB, FCMD and related 
congenital muscular dystrophies (Beltrán-Valero de Bernabé et al., 2002; 
Brockington et al., 2001a; Brockington et al., 2001b; Brown et al., 2004; Driss et al., 
2003; Hayashi et al., 2001; Jimenez-Mallebrera et al., 2003; Longman et al., 2003; 
Michele et al., 2002; Sabatelli et al., 2003; Topaloglu et al., 2003; Walter et al., 
2004). In addition, it was demonstrated that the brain-specific deletion of 
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-dystroglycan gives rise to many of the brain malformations that are also seen in 
WWS, including disorganization of the cortical layers, fusion of cerebral 
hemispheres, discontinuous pial surface and abnormal migration of post-mitotic 
neurons (Moore et al., 2002). Finally, also the Largemyd mouse has altered 
glycosylation of -dystroglycan (Grewal et al., 2001; Michele et al., 2002; Peyrard et 
al., 1999). 
 
 
Figure 4. Schematic representation of the crucial role of dystroglycan (DG) in connecting the 
cytoskeleton of muscle cells with the extracellular matrix. This binding is disrupted by defects in the 
post-translational modification of -DG, causing congenital muscular dystrophy. The O-mannosylation 
is represented by small orange spheres. The composition of these carbohydrate side chains and the 
enzymes that catalyze the addition of these sugar groups are shown in the right panel. Disrupted O-
mannosylation of -DG is seen in Walker-Warburg syndrome (WWS) and muscle-eye-brain disease 
(MEB) patients with mutations in the POMT1 and POMGnT1 genes, respectively, which encode the 
enzymes for the first two steps which cause MEB and WWS when malfunctioning. Similar glycosylation 
defects are seen in patients with mutations in the fukutin, FKRP and LARGE gene, but the role of the 
corresponding proteins is not known. 
Dystroglycan plays a key role in bridging the cytoskeleton of cells with extracellular 
matrix (ECM) proteins. Dystroglycan consists of two subunits, -dystroglycan and 
-dystroglycan, which are obtained upon proteolytic cleavage of a precursor protein 
encoded by a single gene, DAG1. Dystroglycan connects the cytoskeleton to the ECM 
in a number of tissues. In muscle, dystrophin is linked to the actin cytoskeleton and 
binds the transmembranous -dystroglycan. The extracellular domain of 
-dystroglycan connects the ECM by binding to -dystroglycan, which in turn binds 
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to laminin- 2 (Henry and Campbell, 1999) (Figure 4). Hypoglycosylation of 
-dystroglycan in muscle results in a loss of interaction of this protein with the ECM 
protein laminin- 2 and thereby disrupts the link between the sarcolemma of the 
muscle and the ECM (Ervasti and Campbell, 1993; Helbling-Leclerc et al., 1995; 
Winder, 2001). 
The predicted molecular weight of the -dystroglycan protein is about 72 kDa. 
However, on immunoblots, the -dystroglycan protein migrates as a diffuse band of 
150-200 kDa, reflecting the extensive post-translational modification of the protein. 
This increase in molecular weight is largely explained by extensive glycosylation. 
Both N-linked and O-linked glycosylation occur. The level and types of glycosylation 
are likely tissue dependent as judged by different molecular weights. A common 
glycan structure Neu5Ac( 2-3)Gal(ß1-4)GlcNAc(ß1-2)Man( 1)-Ser/Thr is present at 
the central mucin region of -dystroglycan coming from different sources (Chiba et 
al., 1997; Sasaki et al., 1998; Smalheiser et al., 1998). The 
Neu5Ac( 2-3)Gal(ß1-4)GlcNAc part of the sugar chain is required for the binding of 
-dystroglycan to laminin- 2 (Chiba et al., 1997; Endo, 1999; Yamada et al., 1996). 
Using antibodies that recognize a carbohydrate epitope, it was demonstrated that 
cobblestone lissencephaly patients of various types (WWS, MEB and FCMD) have 
undetectable levels of normally glycosylated -dystroglycan in skeletal muscle. In 
contrast, antibodies against the core peptide can detect residual amounts of 
-dystroglycan protein. This apparent glycosylation defect of -dystroglycan is 
strikingly similar for the various syndromes. Muscular -dystroglycan shows a 
reduction of approximately 50 kDa in FCMD and MEB patients as well as in the 
Largemyd mouse. Possibly, failure of glycosylation at any level has the same global 
effects on the total glycosylation of -dystroglycan. In agreement with this is the 
notion that in yeast O-mannosylation may be a prerequisite before N-linked 
glycosylation can occur (Ecker et al., 2003). Very recent work demonstrated that 
overexpression of endogenous LARGE in the Largemyd mouse diminishes muscular 
dystrophy by restoring the hypoglycosylation of -dystroglycan. More strikingly, 
overexpression of LARGE in cells from MEB, FCMD and WWS patients also led to 
the restoration of functionally glycosylated -dystroglycan, indicating that LARGE 
can compensate for the genetically distinct defects in these cells. These data show a 
possible regulatory role for LARGE in glycosylation of -dystroglycan (Barresi et al., 
2004). It has been established that the molecular interaction between LARGE and 
the N-terminal domain of -dystroglycan is crucial for O-linked glycosylation of the 
-dystroglycan mucin domain (Kanagawa et al., 2004). However, it is as yet unclear 
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how overexpression of LARGE can functionally compensate for the genetic defects in 
cells from MEB, FCMD and WWS patients (Barresi et al., 2004). 
WWS candidate genes 
Our genome-wide linkage analyses conducted on 15 consanguineous WWS families 
point to the existence of at least three further WWS loci (Beltrán-Valero de Bernabé 
et al., 2002) (van Reeuwijk, unpublished data). Therefore, the functional candidate 
gene approach in conjunction with homozygosity mapping remains a valid strategy 
to identify other WWS genes. Our prime targets are other components of the 
O-mannosylation pathway and genes known to result in hypoglycosylation of 
-dystroglycan. One excellent candidate gene is the LARGE gene. As discussed 
above, Largemyd mice have an altered glycosylation of -dystroglycan and a 
phenotype that is strikingly similar to the MEB and WWS in humans (Grewal et al., 
2001; Michele et al., 2002; Moore et al., 2002; Peyrard et al., 1999). POMT2 is 
another obvious candidate gene, sharing 36% amino acid identity with POMT1. Both 
genes are expressed in most human tissues, but POMT1 is expressed mainly in fetal 
brain, skeletal muscle and testis whereas POMT2 has its highest expression in testis 
(Jurado et al., 1999; Willer et al., 2002). In Drosophila melanogaster, orthologues of 
the human POMT1 and POMT2 genes cause the rt (rotated abdomen) and tw 
(twisted) phenotypes. These two fly mutants show a similar phenotype with up to 
90% rotation of the abdomen resulting from defects in muscle development. In 
addition, mutant flies have reduced fertility and viability (Martin-Blanco and Garcia-
Bellido, 1996; Willer et al., 2003). Another argument for the possible role for 
POMT2 in WWS is that coexpression of both POMT1 and POMT2 is required to 
obtain POMT enzymatic activity (Manya et al., 2004). This result suggests that a 
heterocomplex is formed between the two proteins during their synthesis, similar to 
what has been observed for the homologous PMT1 and PMT2 proteins (Gentzsch et 
al., 1995; Girrbach and Strahl, 2003). Despite these theoretical considerations, no 
POMT2 mutations were identified in 30 unrelated WWS families (Beltrán-Valero de 
Bernabé et al., 2002). The human genome contains two other genes with some 
homology to POMT1: SDF2 and SDF2L1. Like POMT1/2, these two genes encode 
MIR domains typical of mannosyltransferases, but not the catalytic 
mannosyltransferase domain. The first two steps in the O-mannosyl glycan synthesis 
of -dystroglycan are known to be disrupted in cobblestone lissencephalies by 
mutations in the POMT1 and POMGnT1 genes. It is well possible that disruption of 
other steps in this glycosylation process will give rise to a similar phenotype. The 
addition of galactosyl (step 3) and the addition of N-acetylneuraminic acid (step 4) 
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are performed by the enzymes 1,4-galactosyltransferase ( 4GalT) and -2,3-
sialyltransferase (ST3Gal), respectively. A frameshift mutation in B4GALT1 has been 
implicated in congenital disorder of glycosylation type IId (CDG-IId; MIM 607091). 
This patient had macrocephaly due to Dandy-Walker malformation, hypotonia, 
coagulopathy, myopathy with elevated creatine kinase, mild developmental delay, 
motor retardation and abnormal serum transferrin of which the sialic acid and 
galactose residues were lost (Peters et al., 2002). The enzyme GNE is known to 
catalyze a rate-limiting step in sialic acid biosynthesis and defects result in an 
improper sialylation of glycoproteins (Keppler et al., 1999). Very recently, GNE 
mutations have been linked to hypoglycosylation of -dystroglycan in patients with 
hereditary inclusion body myopathy (MIM600737), an autosomal recessive 
neuromuscular disorder characterized by progressive muscle weakness (Griggs et al., 
1995; Huizing et al., 2004). Although further confirmation of this result is required, 
it indicates that all enzymes involved in O-glycosylation of -dystroglycan are 
candidates for involvement in neuromuscular disorders. The target proteins for O-
mannosylation should also be considered for involvement in cobblestone 
lissencephalies. Currently, the only known O-mannosylated protein is 
-dystroglycan. We have sequenced the entire coding region of -dystroglycan in 11 
linked WWS patients but found no mutations (van Reeuwijk, unpublished data). 
Other target proteins for O-mannosylation may exist, but could be hard to find 
because there is no recognizable motif in the proteins that are targets for 
O-mannosylation in yeast. Other proteins from the DGC complex (Figure 4), 
connecting to or present in the ECM in muscle, the central nervous system and the 
neuromuscular junction are possible WWS candidate genes. An important ligand of 
-dystroglycan in the ECM of muscle is laminin- 2 (merosin), mutations of which 
cause MDC1A (MIM 607855), a common form of CMD and clinically related to 
FCMD. 
Conclusions and perspectives 
In the past few years, hypoglycosylation of -dystroglycan has been found to be the 
mechanism linking several neuromuscular diseases. This list includes WWS, MEB, 
FCMD, MDC1C, MDC1D, LGMD2I and some intermediate phenotypes (Figure 2). 
Of these, WWS shows the most severe clinical features including CMD, severe brain 
and eye involvement. It has been shown that mutations in POMT1, fukutin and 
FKRP may each give rise to WWS. Knowing that mutations in most of the genes 
involved in WWS and related disorders show a wide clinical range, mutations in 
POMGnT1 and LARGE should also be sought in WWS patients. In view of the 
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genotype-phenotype correlation, we also hypothesize that mild mutations in POMT1 
might cause MEB or even FCMD. It has been shown that POMT1 and POMGnT1 are 
responsible for the addition of an O-linked mannose and a N-Acetylglucosamine 
residue, respectively, to -dystroglycan (Manya et al., 2004; Yoshida et al., 2001). 
Elucidation of the exact function of fukutin, FKRP and LARGE in O-mannosyl 
glycan synthesis could lead to further candidate genes for WWS. For this, a better 
understanding of the post-translational modification of -dystroglycan will be 
crucial. Genome-wide homozygosity mapping in consanguineous WWS families may 
lead to the identification of further genes involved in these disorders. The genetic 
heterogeneity in WWS and related disorders imposes some difficulties for diagnostic 
studies and genetic counseling. Presently, mutation analysis for POMT1 and 
POMGnT1 is available in a diagnostic setting 
(http://www.dnadiagnostieknijmegen.nl), and we emphasize to include the other 
cobblestone lissencephaly genes in the future. Recently, enzymatic assays have been 
described to test the activity of POMT1 and POMGnT1 and to diagnose for the 
founder mutation in FCMD (Kato et al., 2004; Manya et al., 2004; Zhang et al., 
2003). These tests in combination with mutation analysis of the known cobblestone 
lissencephaly genes should allow prenatal diagnosis in selected families. 
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Abstract 
Walker-Warburg syndrome is an autosomal recessive condition characterised by 
congenital muscular dystrophy, structural brain defects, and eye malformations. 
Typical brain abnormalities are hydrocephalus, lissencephaly, agenesis of the corpus 
callosum, fusion of the hemispheres, cerebellar hypoplasia, and neuronal 
overmigration, which causes a cobblestone cortex. Ocular abnormalities include 
cataract, microphthalmia, buphthalmos, and Peters anomaly. Walker-Warburg 
syndrome patients show defective O-glycosylation of -dystroglycan, which plays a 
key role in bridging the cytoskeleton of muscle and central nervous system cells with 
extracellular matrix proteins, important for muscle integrity and neuronal 
migration. In 20% of the Walker-Warburg syndrome patients, hypoglycosylation 
results from mutations in either POMT1, FKTN, or FKRP. The other genes for this 
highly heterogeneous disorder remain to be identified. To look for mutations in 
POMT2 as a cause of Walker-Warburg syndrome, as both POMT1 and POMT2 are 
required to achieve protein O-mannosyltransferase activity, we combined a 
candidate gene approach with homozygosity mapping. Homozygosity was found for 
the POMT2 locus at 14q24.3 in four of 11 consanguineous Walker-Warburg 
syndrome families. Homozygous POMT2 mutations were present in two of these 
families as well as in one patient from another cohort of six Walker-Warburg 
syndrome families. Immunohistochemistry in muscle showed severely reduced 
levels of glycosylated -dystroglycan, which is consistent with the postulated role for 
POMT2 in the O-mannosylation pathway. A fourth causative gene for 
Walker-Warburg syndrome was uncovered. These genes account for approximately 
one-third of the Walker-Warburg syndrome cases. Several more genes are 
anticipated, which are likely to play a role in glycosylation of -dystroglycan. 
Introduction 
Walker-Warburg syndrome (WWS) is a congenital disorder characterised by 
multiple anomalies of the brain, muscle, and eye. This combination of 
malformations is also found in muscle-eye-brain disease (MEB) and in Fukuyama 
congenital muscular dystrophy (FCMD). The most severe anomalies are seen in 
WWS patients, especially with regard to the brain malformations. Brain 
malformations typical of WWS are agyria, agenesis of the corpus callosum, 
cerebellar vermis and septum, and occasional occipital encephalocele (Cormand et 
al., 2001; Dobyns et al., 1989; van Reeuwijk et al., 2005a). The pathogenesis 
underlying WWS, MEB, FCMD, and other congenital muscular dystrophies (CMD) 
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such as congenital muscular dystrophy 1C (MDC1C) and 1D (MDC1D) involves 
functional disruption of -dystroglycan by mutations in genes that are involved in 
O-mannosylation of this protein (Dalkilic and Kunkel, 2003; Endo and Toda, 2003; 
Grewal and Hewitt, 2003; Martin and Freeze, 2003; Martin-Rendon and Blake, 
2003; Muntoni et al., 2004; Schachter et al., 2004). The O-linked carbohydrate 
chains of -dystroglycan are an important component of the dystrophin glycoprotein 
complex which mediates the interaction between the extracellular matrix and the 
cytoskeleton of muscle cells and neurons (Kanagawa et al., 2004; Kim et al., 2004; 
Martin, 2003; Michele et al., 2002; Michele and Campbell, 2003). A common 
O-mannosyl glycan structure found on -dystroglycan is 
Neu5Ac 2-3Gal 1-4GlcNAc 1-2Man 1-Ser/Thr (Endo, 1999; Willer et al., 2003). 
The first step in the synthesis of this glycan structure takes place in the endoplasmic 
reticulum by one or more proteins from a family of well conserved protein 
O-mannosyltransferases (PMTs). These proteins catalyse the transfer of a mannose 
from dolichyl phosphate activated mannose to serine or threonine residues of 
secretory proteins. In yeast, a family of seven PMTs (Pmt1p to Pmt7p) are known. 
Double and triple mutants of the PMTs in yeast indicate that proper 
O-mannosylation is required for its cell wall rigidity and cell integrity (Gentzsch and 
Tanner, 1996). In Drosophila and human there are only two orthologues: POMT1 
and POMT2 (Willer et al., 2003). RNAi knockdown of either POMT1 or POMT2 in 
Drosophila causes a rotation of the abdomen by 30–60˚, demonstrating the 
requirement of both POMT1 and POMT2 for normal muscle development in the fly 
(Ichimiya et al., 2004). No embryonic nervous system or eye abnormalities were 
observed for POMT1 knockouts (Martin-Blanco and Garcia-Bellido, 1996). In 
addition, it has been shown that in humans POMT1 and POMT2 are also both 
required for O-mannosyltransferase activity (Ichimiya et al., 2004; Manya et al., 
2004). Previously we have shown that mutations in either POMT1, FKTN, or FKRP 
result in hypoglycosylation of -dystroglycan, giving rise to the autosomal recessive 
disorder WWS (Beltrán-Valero de Bernabé et al., 2002; Beltrán-Valero de Bernabé 
et al., 2003; Beltrán-Valero de Bernabé et al., 2004). The phenotypic similarity seen 
in the fly knockdown of POMT1 and POMT2 and the simultaneous requirement for 
both proteins to obtain O-mannosyltransferase in fly as well as human made us 
reconsider POMT2 as candidate gene for WWS. In this study we show that POMT2 
mutations also cause WWS. 
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Methods 
Genetic analysis Using standard methods we extracted DNA from peripheral 
blood lymphocytes. Genome-wide homozygosity mapping was carried out at our 
linkage facility using the 10 cM spaced microsatellite marker set from Applied 
Biosystems (ABI Prism linkage mapping set version 2, Applied Biosystems, Foster 
City, California, USA) and at MRC geneservice in Cambridge with use of the 
GeneChip Mapping 10K 2.0 arrays from Affymetrix (Santa Clara, California, USA). 
Additional homozygosity mapping for POMT2 was undertaken by polymerase chain 
reaction (PCR) of the flanking microsatellite markers D14S279, D14S983, and 
D14S59, which were subsequently resolved on 8% polyacrylamide sequencing gels 
and developed by silver staining. 
Mutation analysis All 21 exons of the POMT2 gene were amplified using 
specific primers for the 5‟- and 3‟-flanking intron sequences. Primers and PCR 
conditions are given in Table 1. After purification from agarose gels, the PCR 
products were used for direct sequencing using the BigDye terminator kit (Perkin 
Elmer Applied Biosystems, Norwalk, Connecticut, USA), which were analysed on an 
ABI3700 capillary sequencer. The presence of the identified mutations in the normal 
population was tested by restriction enzyme analysis in chromosomes from control 
individuals. For this, the relevant amplicon was digested with TaqI (c.1912C>T), 
HpyCH4 IV (c.1005+1G>A), and NciI (c.1261delC) (New England BioLabs, Beverly, 
Massachusetts, USA). 
Immunohistochemistry Muscle biopsies from control and WWS patients 
were obtained after informed consent of patients and approval of the ethics 
commission. Myoblast cell cultures were established by enzymatic and mechanical 
treatment of muscle biopsies and by plating in Dulbecco‟s modified Eagle‟s medium 
plus fetal calf serum, penicillin, streptomycin, and amphotericin B (Sigma, Poole, 
Dorset, UK) (Cenni et al., 2005). Myotubes were obtained by confluent myoblast 
cultures allowed to differentiate for seven days in cultures medium. Samples for 
immunohistochemical analysis were fixed in 2% paraformaldehyde in phosphate 
buffer saline (PBS) and incubated overnight with an anti- -dystroglycan 
monoclonal antibody (VIA4-1, Upstate Biotechnology, Lake Placid, New York, USA) 
diluted 1/50, washed with PBS and then with an antimouse IgG TRITC conjugated 
antibody (Dako, Glostrup, Denmark). The same sample was then incubated with a 
polyclonal anti-caveolin 3 antibody (Santa Cruz Biotechnology, Santa Cruz, 
California, USA) diluted 1/50 followed by FITC conjugated anti-goat antibody. The 
sample was washed in PBS, mounted in Pro-long anti-fade reagent (Molecular 
Probes, Eugene, Oregon, USA), and examined with a Nikon epifluorescence 
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microscope at a magnification of x500. Immunohistochemistry on muscle biopsies 
was carried out as was previously described (Jimenez-Mallebrera et al., 2003). In 
Brief, frozen 8 mm sections were incubated with primary monoclonal antibodies to 
-dystroglycan (NCL- -dystroglycan, Novocastra Laboratories, Newcastle upon 
Tyne, UK), -dystroglycan (IIH6, Upstate Biotechnology), and sheep polyclonal 
antibody recognizing the core protein of -dystroglycan (Herrmann et al., 2000). 
These were than revealed with an appropriate biotinylated secondary antibody 
(Amersham 1:200; Amersham Life Sciences, Amersham, UK) followed incubation 
with streptavidin conjugated to Alexa 594 (Molecular Probes) and visualised by 
epifluorescence microscopy. 
 
Table 1. Primer sequences and conditions for PCR amplification of POMT2 
Exon Forward primer Reverse primer Product length 
(bp) 
PCR annealing  
temp (°C) 
1 ggagttgcagttccctgagc taccctcgggccaatcagag 609 58 
2 ccatgctttatgaaggccatttg tggctccagcccttaggaac 224 58 
3 gcagctggagggaagttcag ttagtgtggccccagggttc 235 58 
4 tcatcaggtcccctgtcttaaatg gggcccttgaatgtactgattttc 294 58 
5 gtttcctactactggggtgcttgg acagaaattttggagttgccacag 250 58 
6 aagacagggcacagcacagc ccagaacacagccactctgc 384 58 
7 ggctggcccatgtttatcttg agggtgctggcctttctgag 502 58 
8 tccatcacccacctctgtcc ctttctcccaccgtgccatc 339 58 
9 ttagtgagccctgtggcttcc tgtcatggcgaacagcattg 255 58 
10 tggctggggattctgaaattg tcagcaaagcccatctcagg 304 58 
11 ggggtctttcctctttggtctc tgtggccttgctccattgac 353 58 
12 ggtttgggctcatctcttctcc tccctgtgcagcctcttatcc 403 58 
13 gccatttccctttctgacacg gcagacagcaggtgaacacag 334 58 
14 ggaaaagagaaggagcctgtgg cggagggagtggatgagaag 386 58 
15 ctggtgggaatgtggacacc attcatggctgcccaaaagc 214 58 
16 ctgggccccacatttctgtc cggtctccctgctcttgttc 203 58 
17 tcctccccctaatgggtgtg ggaatgggcagatgagaacg 207 58 
18 gcgttctcatctgcccattc ggtggtaaacgcaaaggatgg 246 58 
19 acagcaaggaaggggcagag tgctctgtctcccaagtccag 263 58 
20 cctggctgactccaggtttc acactgggagggcatgtgag 185 58 
21 agctccagcaggaggaatgg ttccagctgcactcccagag 342 58 
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Results 
Direct linkage mapping of candidate genes using genome-wide 
homozygosity data We carried out genome-wide homozygosity mapping of 12 
WWS patients from 11 unrelated consanguineous families in which linkage to the 
known WWS loci (POMT1, fukutin, and FKRP) has been excluded. Depending on the 
amount of DNA available we used the 10 cM spaced microsatellite marker set (ABI 
Prism linkage mapping set version 2) or the GeneChip Mapping 10K 2.0 Array 
(Affymetrix). As can be expected from the genetic heterogeneity of WWS, these 
homozygosity mapping results of mostly singletons failed to point to a single WWS 
locus and indeed indicated further genetic heterogeneity. Although we failed to 
detect POMT2 mutations in an earlier study of 24 WWS families (Beltrán-Valero de 
Bernabé et al., 2002), we targeted POMT2 as a candidate gene based on the premise 
that all three previously identified WWS genes, POMT1, fukutin, and FKRP, are 
involved in O-mannosyl glycan synthesis. A similar function is likely for POMT2, 
based on the overlapping expression profiles and homologous amino acid 
composition compared with POMT1. In addition, recent reports indicate that 
POMT2 is required for the enzymatic activity of POMT1 in human as well as 
Drosophila (Ichimiya et al., 2004; Manya et al., 2004). Our new mapping data 
indicated possible linkage to the POMT2 locus in four of 11 unrelated WWS families. 
Mutation analysis of POMT2 Mutation analysis in all four families led to 
the identification of mutations in two of these, a nonsense mutation (c.1912C>T, 
p.R638X) in patient 1 and a splice site mutation (c.1005+1G>A) in patient 2, both 
found in homozygosity. Both mutations result in the disruption of a restriction site 
for Taq1 and HpyCH4 IV, in exon 19 and exon 8, respectively. These disruptions 
were not observed in control individuals digested with Taq1 (170 chromosomes) and 
HpyCH4 IV (290 chromosomes). 
No mutations were detected in the POMT2 exons in the other two families that 
showed linkage to the POMT2 locus. Reasons for this could be that their linkage was 
a fortuitous finding or that a mutation resides in parts of the POMT2 gene such as an 
intron or a regulatory element that have not been analysed. An additional six 
consanguineous WWS families were then tested for homozygosity at the POMT2 
locus. In two of these WWS families the data were consistent with linkage to 
POMT2. We identified a homozygous 1-bp deletion (c.1261delC) in one these 
families. This mutation introduces a premature stop codon (p.T433X). The mutation 
was also homozygously present in an affected sibling and disrupts one of the two 
restriction sites for NciI in exon 12, which was used to verify the absence of this 
mutation in 140 control chromosomes from the normal population.  
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Pedigrees and DNA sequencing results of the three POMT2 mutated families are 
shown in Figure 1. 
Clinical description WWS patients with POMT2 mutations Patient 1 is 
a girl born to uncle-niece consanguineous Moroccan parents. A prenatal ultrasound 
indicated hydrocephalus which was confirmed by magnetic resonance imaging, 
which also showed type II lissencephaly (Figure 2, panels A and B). At birth at 37 
weeks gestation, her weight was 3150 grams, and her head circumference was 36 cm. 
The child was severely hypotonic. Ophthalmological examination showed bilateral 
Peters anomaly with cataracts, left sided microphthalmia, and right sided 
buphthalmos. The creatine kinase was greatly raised at 12144 U/l. MRI of the brain 
documented hydrocephalus, cobblestone lissencephaly, and aplasia of the corpus 
callosum. 
 
Figure 1.  POMT2 mutations in families with Walker-Warburg syndrome (WWS). For each of the 
families with POMT2 mutations the pedigrees and DNA sequencing results are shown. Mutations are 
indicated with an asterisk (*). Patient 1 is homozygous for a nonsense mutation in exon 19 (c.1912C>T, 
p.R638X). The mutation in this patient is preceded by a known polymorphism indicated by a § sign. 
Patient 2 is homozygous for a mutation in intron 8 (c.1005+1G>A) which is predicted (Reese et al., 1997) 
to result in the disruption of the donor site for intron splicing of intron 8. This mutation also disrupts a 
restriction site for the HpyCH4 IV enzyme and was not present in 100 chromosomes of controls. Patient 
3 is homozygous for a deletion of 1-bp in exon 12 (c.1261delC) which tends to a premature stop codon 
(p.T433X). The same mutation was found heterozygously in both parents and homozygously in an 
affected sibling in this family. 
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Patient 2 is a male child born to first cousin Pakistani parents. Severe hydrocephalus 
was diagnosed prenatally on ultrasound and the child was delivered by caesarean 
section. A left-sided cleft lip and palate were diagnosed. Imaging of the brain by MRI 
revealed aplasia of the posterior vermis, hypoplasia of the pons and cerebellum, 
severe hydrocephalus, and a cobblestone cortex (Figure 2, panels C and D). 
Ophthalmological investigation documented bilateral cataracts and persistent 
pupillary membrane. The retina could not be visualised. A muscle biopsy was 
consistent with a diagnosis of congenital muscular dystrophy. There was increased 
variability of fibre diameter, increased endomysial fibrosis, and basophilic 
regeneration. External genitalia were normal. The child died at the age of six 
months. 
 
 
 
Figure 2. Brain magnetic resonance imaging of patient 1 at two days of age (A and 
B) and patient 2 at 16 months of age (C and D). Both patients show hydrocephalus, 
dilatation of the ventricles, agyria, cerebellar hypoplasia, and absence of the corpus 
callosum. 
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Patient 3 is a male infant referred at the age of two months and one week because of 
severe neonatal hypotonia, developmental delay, and poor visual behaviour, as 
previously reported (Jimenez-Mallebrera et al., 2003). He was the third child of a 
consanguineous Bengali family. His older siblings were healthy. Congenital 
hydrocephalus required a shunt at two weeks of age. Serum creatine kinase was 
markedly raised. Ophthalmological examination showed bilateral lamellar cataracts, 
and buphthalmos caused by anterior chamber anomalies. He had no head control 
and no apparent response to visuoacoustical stimuli. Brain MRI at the age of five 
weeks showed severe hydrocephalus with a thin and smooth cortical mantle. The 
patient died at eight months of age during a respiratory infection. A further sibling 
was diagnosed prenatally with severe hydrocephalus at 18 weeks‟ gestation. This 
pregnancy was subsequently terminated. 
Histopathology of WWS muscle tissue Immunolabelling of the 
glycoepitope of -dystroglycan with the VIA4-1 antibody (Ervasti and Campbell, 
1991) in cultured myotubes from patient 2 showed markedly reduced staining 
compared with control myotubes (Figure 3, panels A and B). Control labelling with 
anti-caveolin3, a marker of muscle differentiation, showed that -dystroglycan co-
localises with caveolin3 at the sarcolemma of myotubes derived from a control 
individual (Figure 3C). Similar normal staining was observed in myotubes derived 
from patient 2 (Figure 3D). 
Reduced staining of -dystroglycan was also observed in patient 3 by 
immunolabelling of the core and glyco-epitope of -dystroglycan (Figure 4, panels 
D and F). Normal staining was observed for -dystroglycan in control muscle 
(Figure 4, panels C and E). -dystroglycan staining was normal in the patient as 
well as in the control (Figure 4, panels A and B). Reduction of immunolabelling of 
-dystroglycan and a mild reduction of laminin- 2 in muscle tissue from patient 3 
were described previously (Jimenez-Mallebrera et al., 2003). No muscle tissue was 
available for patient 1. 
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Control Patient 2 
 
 
Figure 3. Immunofluorescence analysis of cultured myotubes obtained from a control 
individual (A and C) and patient 2 (B and D). A double labelling was carried out with anti-
-dystroglycan glycoepitope antibody (VIA4-1) (A and B), and anti-caveolin3, a marker of 
muscle differentiation (C and D). These were visualised using an anti-mouse TRITC conjugated 
secondary antibody and an anti-goat FITC conjugated antibody, respectively. In control 
myotube, -dystroglycan labelling co-localises with caveolin3 at the sarcolemma. In the WWS 
patient myotube, caveolin 3 was expressed with a pattern similar to the control myotube while 
-dystroglycan staining was severely reduced. Magnification x500. 
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Control Patient 3 
 
 
Figure 4.  Muscle biopsy of control muscle (A, C, and E) and patient 3 (B, D, and F). 
Immunostaining with antibodies to -dystroglycan was normal in both patient and control muscle 
(A and B). Immunostaining with antibodies that recognise core -dystroglycan (C and D) and a 
glycosylated epitope (IIH6) of dystroglycan (E and F) showed normal expression in control but 
marked reduction of staining in the patient. 
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Discussion 
We have detected three homozygous mutations in POMT2 in three families with 
typical WWS. The mutations included a nonsense mutation resulting in a premature 
stop codon, a splice site mutation, and a 1-bp deletion leading to a premature stop 
codon. All mutations were homozygous in the patients (Figure 1). The phenotype 
seen in these WWS patients is indistinguishable from that of patients with POMT1, 
FKTN, or FKRP mutations. One of the sibpair from family 3 who carries a 
homozygous 1-bp deletion mutation was described earlier, and hypoglycosylation of 
-dystroglycan (Figure 4) and a possible reduction of laminin- 2 in muscle tissue 
were documented (Jimenez-Mallebrera et al., 2003). Absence of glycosylated 
-dystroglycan was also seen in a muscle biopsy from patient 2 in the present study 
(Figure 3). This is consistent with the postulated role of O-glycosylation in normal 
neuromuscular, brain, and eye development (Michele et al., 2002; Moore et al., 
2002). Although previously no enzymatic activity of POMT1 and POMT2 was 
determined in vertebrates, the involvement of POMT1 in WWS, the high amino acid 
identity between the two paralogs, and the overlapping expression pattern was 
reason to hypothesise that mutations in POMT2 also give rise to WWS (Willer et al., 
2002). For this reason we previously undertook mutation analysis of POMT2 in 24 
unrelated patients but no causative mutations were detected (Beltrán-Valero de 
Bernabé et al., 2002). In this study, 17 additional families where investigated, of 
which six showed possible linkage to the POMT2 locus. We found POMT2 mutations 
in three of these (Figure 1), resulting in a frequency of 7% (3 of 41 families). Thus 
the incidence of POMT2 mutations appears to be in the same range as that of 
POMT1. POMT1 mutations were previously detected at a frequency of 20% and 7% 
in two large samples of WWS patients (Beltrán-Valero de Bernabé et al., 2002; 
Currier et al., 2005). This is in accordance with the requirement of both proteins to 
obtain O-mannosyltransferase activity (Ichimiya et al., 2004; Manya et al., 2004). So 
far, mutations in POMT1, POMT2, fukutin, and FKRP together explain almost 
one-third of the WWS patients in our cohort. The majority of WWS cases remain 
unexplained and further genetic heterogeneity is likely from our genome-wide 
homozygosity data.  
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Abstract 
Intragenic homozygous deletions in the Large gene are associated with a severe 
neuromuscular phenotype in the myodystrophy (myd) mouse. These mutations 
result in a virtual lack of glycosylation of -dystroglycan. Compound heterozygous 
LARGE mutations have been reported in a single human patient, manifesting with 
mild congenital muscular dystrophy and severe mental retardation. These mutations 
are likely to retain some residual LARGE glycosyltransferase activity as indicated by 
residual -dystroglycan glycosylation in patient cells. We hypothesized that more 
severe LARGE mutations are associated with a more severe congenital muscular 
dystrophy phenotype in humans. Here we report a 63-kb intragenic LARGE deletion 
in a family with Walker-Warburg syndrome, which is characterized by congenital 
muscular dystrophy, and severe structural brain and eye malformations. This finding 
demonstrates that LARGE gene mutations can give rise to a wide clinical spectrum, 
similar as for other genes that have a role in the post-translational modification of 
the -dystroglycan protein. 
Introduction 
Abnormal O-linked glycosylation of -dystroglycan is the common pathogenic 
mechanism in a group of patients with a clinical spectrum ranging from severe 
congenital muscular dystrophy (CMD), structural brain, and eye abnormalities 
[Walker-Warburg syndrome (WWS), MIM 236670] to a relative mild form of 
limb-girdle muscular dystrophy (LGMD2I, MIM 607155) (van Reeuwijk et al., 
2005a). In muscle tissue, -dystroglycan acts as a bridge between the extracellular 
matrix laminin- 2 and the actin cytoskeleton through the transmembranal 
-dystroglycan. The interaction of -dystroglycan with the extracellular matrix 
proteins is mediated by its O-glycosylated moiety. Mature -dystroglycan in brain 
binds to laminin- 2 and neurexin, which is important for neuronal migration in the 
neocortex and the integrity of the glia limitans (Barresi and Campbell, 2006). 
Mutations that result in hypoglycosylation of -dystroglycan have been identified in 
known and putative glycosyltransferase genes: FKTN, FKRP, LARGE, POMGnT1, 
POMT1, and POMT2 (Freeze, 2006). Four of these genes, FKTN, FKRP, POMT1, and 
POMT2, have been implicated in WWS. These genes explain approximately one-
third of the WWS patients in our cohort. Interestingly, different mutations in these 
genes are known to cause phenotypic variability ranging from WWS to limb-girdle 
muscular dystrophy. Thus, it appears that mutations in genes that affect the 
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glycosylation of -dystroglycan can give rise to a number of related disorders, 
thereby blurring the boundaries between these clinically defined 
„dystroglycanopathies‟ (Freeze, 2006; Mercuri et al., 2006a; van Reeuwijk et al., 
2005a; van Reeuwijk et al., 2006). Here, we have investigated whether allelic 
variability does also occur for the LARGE gene. 
The LARGE protein is a putative glycosyltransferase, required for addition of as yet 
unknown glycans onto the -dystroglycan protein. Interestingly, overexpression of 
LARGE can by-pass the glycosylation defects in cells from patients with WWS or 
muscle-eye-brain disease (MEB, MIM 253280) (Barresi et al., 2004). Mutations in 
LARGE have been identified in a patient with relatively mild CMD and severe mental 
retardation (MDC1D: MIM 608840). This patient is compound heterozygous for 
p.E509K and p.C667fs. These mutations do not seem to abolish the activity of the 
LARGE protein completely, as Western blot analysis of skeletal muscle from this 
patient indicates residual functional glycosylation and laminin- 2 binding activity 
for -dystroglycan (Longman et al., 2003). Interestingly, myd mice that carry a 
spontaneous deletion in Large (Largemyd), resemble the more severe clinical 
Fukuyama congenital muscular dystrophy (FCMD, MIM 253800), and MEB (Grewal 
et al., 2001; Longman et al., 2003; Michele et al., 2002). 
Based on linkage studies we expect that there are multiple other genes that give rise 
to a WWS phenotype when mutated (van Reeuwijk et al., 2005b) (unpublished 
data). Here we report a homozygous 63-kb intragenic deletion in LARGE, in a 
patient who had familial classical WWS characteristics. This result establishes 
LARGE as the fifth WWS gene. 
Patients and methods 
Case reports Patient 1 is a Saudi female and was delivered normally at term. 
Parents were second-degree cousins. Mother was gravida 5 para 4 with uneventful 
pregnancy, no polyhydramnios, or reduced fetal movements. Apgar scores were 5 
and 8 at 1 and 5 min, respectively. Birth weight 2,880 g (25th centile), length 50 cm 
(50th centile), head circumference 37 cm (>90th centile). Physical examination 
(Figure 1A) showed no dysmorphic features, severe generalized hypotonia with 
very little spontaneous movements of the limbs and valgus deformity of the feet. She 
had poor respiratory effort. Anterior fontanel was wide with separated sutures, deep 
tendon reflexes were absent, and sensation was intact. Ophthalmic examination 
revealed dense bilateral congenital cataract in the left eye and mild lens opacity with 
pigmentary degeneration of the retina and optic atrophy in the right eye. She was 
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discharged from the Neonatal Intensive Care Unit at the age of 3 months. At the age 
of 4 months her weight was on the 25th centile, length 10th centile and head 
circumference above 95th centile. She was developmentally delayed and blind. She 
died at the age of 6 months. 
Laboratory investigations showed remarkably high creatine kinase (CK) of 28,600 
U/l (N 24–170) on the third day of life and 1,086 U/l at the age of 1 month. Liver 
function tests, metabolic screens, and TORCH panel for congenital infections were 
all normal. Chromosome analysis was normal female karyotype. Brain computed 
tomography (CT) (Figure 1B and C) showed marked dilatation of the lateral 
ventricles with moderate dilatation of the third ventricle, there was a striking 
decrease in attenuation surrounding the dilated ventricles, the inferior cerebellar 
vermis was absent, and the cerebellum was hypoplastic. Electroencephalogram 
showed frequent right tempro-occipital burst of sharp and slow activity. Brain 
auditory evoked responses using monoaural click stimulation were normal. Muscle 
biopsy showed features of dystrophy. A diagnosis of WWS was made based on 
central nervous system, eye, and muscle involvement. No DNA or tissue sample were 
available for this study. 
 
Figure 1. Phenotype and brain CT scans of patient 1 (A–C) and patient 2 (D–F). Patient 1 showed no 
dysmorphic features, severe generalized hypotonia with very little spontaneous movements of the limbs, 
and valgus deformity of the feet (A). Brain CT of patient 1 (B and  C), and patient 2 (E and F) show 
absence of the inferior cerebellar vermis, a hypoplastic cerebellum, and marked dilatation of the lateral 
ventricles. Patient 2 also shows severe hydrocephalus with wide fontanel and separated sutures and cysts 
(D–F). 
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Patient 2 is the younger sibling of patient 1. Antenatal ultrasound showed 
hydrocephalus and he was delivered by emergency cesarean section. Apgar scores 
were 6 and 9 at 1 and 5 min, respectively. Physical examination (Figure 1D) showed 
severe hydrocephalus with wide fontanel and separated sutures, and head 
circumference was 46 cm, above the 97th centile. He had generalized hypotonia, 
absent deep tendon reflexes but no dysmorphic features. Ophthalmic examination 
showed bilateral leukocornia, retinal dysplasia, and posterior synechia. Brain CT 
(Figure 1E and F) revealed severe hydrocephalus with Dandy-Walker malformation 
and minimal brain tissue, absent inferior cerebellar vermis and hypoplastic 
cerebellum. CK was elevated at 18,000 U/l (N 24–195). Lactate dehydrogenase was 
high at 1,690 U/l (N 230–460). Liver enzymes were mildly elevated, alanine 
aminotransferase 53 U/l (N 10–50), and aspartate aminotransferase 142 U/l (N 10–
45 U/l). Tandem mass spectrometry for metabolic screen was unremarkable; 
TORCH for congenital infections was negative. Chromosome analysis showed 
normal male karyotype. Muscle biopsy was done at the age of 11 days and revealed 
dystrophic features in the form of myofiber necrosis, basophilic fibers and interstitial 
endomysial, and perimysial fibrosis. There was no specific fiber type atrophy or 
grouping. A limited number of immunostains were done and included dystrophin 
and -sarcoglycan. Both immunostains were normally positive.  
A ventriculoperitoneal shunt was inserted. He was 
weaned of the ventilatory support and died at the 
age of 2 months. A diagnosis of WWS was made. 
Nine other siblings were born healthy and DNA was 
obtained from seven, as well as the parents. A 
pedigree of the family is given in Figure 2. 
Linkage analysis and mutation analysis
 DNA was extracted from blood lymphocytes 
using standard procedures. Linkage to the LARGE 
locus was assessed by genotyping two microsatellite 
markers flanking the gene (D22S281 and D22S529) 
and two intragenic markers (D22S1162 and 
D22S1172). Primer3 (http://www.frodo.wi.mit.edu) 
was used to design specific primers for PCR 
amplification and direct sequencing of the 14 coding 
exons (including intron–exon boundaries) of 
LARGE (NM_004737.3). 
  
 
 
Figure 2. Family pedigree. Females 
are represented by circles, males by 
squares. Open symbols represent 
the unaffected family members, the 
solid black symbols the WWS 
affected siblings. 
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Copy number detection 
Copy number detection of the 16 LARGE exons was performed by Multiplex 
Amplifiable Probe Hybridization (MAPH). A series of probes for the 16 LARGE 
exons were generated by PCR and cloned into pZERO (Invitrogen, Carlsbad, CA, 
USA). MAPH was carried out and probe ratios analyzed essentially as previously 
described (Armour et al. 2000; Hollox et al. 2002). Multiplex Ligation-dependent 
Probe Amplification (MLPA) was used to further restrict the deletion breakpoints. 
MLPA probes were designed within exons 8–11 and intron 8 and 10 of the LARGE 
gene. A protocol for designing these probes and  
hybridization, ligation, and amplification of these probes is provided by MRC-
Holland (http://www.mlpa.com). Product separation was performed using capillary 
electrophoresis on an ABI 3730 or 3100 sequencer (Applied Biosystems, Foster City, 
CA). For quantitative analysis, trace data were retrieved using Genemapper software 
following the manufacturer‟s protocol (Applied Biosystems). 
Long-range PCR method and sequence analysis of breakpoints 
The breakpoint-spanning region was amplified by long-range PCR amplification 
with specific primers and LA TaqTM (TaKaRa Bio Inc., Shiga, Japan) using PCR 
conditions recommended by the manufacturer. We then used different combinations 
of primers to further restrict the breakpoint-spanning region and identified the 
breakpoint by direct sequencing. 
Results 
Linkage to the LARGE locus and mutation analysis 
We hypothesized that severe LARGE mutations give rise to WWS. To assess this 
hypothesis we selected intragenic and LARGE flanking genetic markers to test for 
homozygosity in 30 WWS patients from consanguineous parents. Seven patients 
from six unrelated families showed homozygosity for at least two intragenic markers 
(D22S1162 and D22S1172) and one marker (D22S281 or D22S529) in close 
proximity of LARGE. 
We performed mutation analysis for all 14 coding exons including intron–exon 
boundaries by direct sequence analysis. No mutations were found. However, 
difficulties during the PCR amplification of some of the exons suggested a possible 
deletion of these exons in one of the families. Two affected siblings in this family 
manifest typical WWS features as described in the patients and methods section. 
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Identification of a submicroscopic deletion by copy number detection 
Using MAPH we screened all 16 exons for copy number changes. Exon 9 and 10 
showed copy number changes in one family, indicative for a deletion of these exons 
in patient 2 (homozygous) and in the parents (hemizygous). This result was 
confirmed by MLPA analysis of probes specific to these exons and surrounding 
intronic sequences, which also further defined the size of the deletion to 61.1-66.6 kb 
(Figure 3). 
Analysis of breakpoints 
By long-range PCR amplification we obtained a deletion-spanning fragment of 
~3.5-kb from patient 2. Sequence analysis of this fragment revealed the 5‟ and 3‟ 
breakpoints, and a deletion size of 63.1-kb (Figure 4). This genomic deletion 
predicts a 239-bp deletion in the transcript resulting in a shift of the open reading 
frame within the first predicted catalytic domain, coding for 29 alternative codons 
followed by a premature stop codon, which most likely results in nonsense-mediated 
decay of the transcript. Unfortunately no cell-line or tissue sample was available to 
test this hypothesis. Only the affected individual was homozygous for the deletion, 
the parents and five of the seven analyzed unaffected sibs were heterozygous carriers 
of the deletion. No significant match between the 5‟ and 3‟ junction sequences is 
present, therefore the LARGE deletion is likely the result of non-homologous end-
joining as reported also for the Large deletion in myd mice (Browning et al., 2005). 
 
 
Figure 3. MLPA analysis, 
showing a deletion of two 
exonic probes (EX9 and 
EX10) and two flanking 
intronic probes (IN8-2 and 
IN10) in the patient 
(diamonds), and in the 
unaffected carriers (black 
circles, triangles, and 
squares). No intronic probes 
were tested for the patient 
due to limited availability of 
DNA. Open circles, triangles, 
and squares depict control 
individuals. 
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Figure 4. Schematic overview of LARGE exons 8–11 of wild-type sequence (A) and patient sequence 
(B), showing the exons depicted by black boxes and the MLPA probes depicted by black bars. MLPA 
analysis revealed deletion of four MLPA probes (IN8-2, EX9, EX10, and IN10). Sequence analysis of the 
breakpoint region in the patient revealed the exact position of the 63.1-kb deletion (C). 
Discussion 
We previously reported mutations in POMT1, POMT2, FKTN, and FKRP in 
approximately one-third of the WWS patients in our cohort (Beltrán-Valero de 
Bernabé et al., 2002; Beltrán-Valero de Bernabé et al., 2003; Beltrán-Valero de 
Bernabé et al., 2004; van Reeuwijk et al., 2005b). Here we report a homozygous 
63-kb intragenic deletion in LARGE in a patient with WWS. The clinical features of 
the patients in this family do not diverge from the typical manifestations of other 
WWS patients. Hence, none of the five WWS genes that are known to date are 
associated with discriminating clinical features. The deletion described in this report 
is likely a loss-of-function mutation due to a predicted frameshift of the open 
reading frame within the first predicted catalytic domain. Mice carrying a similar 
disruptive defect in the Large gene display a severe muscle, eye, and brain 
phenotype, and have a shortened life span. With regard to the brain defects, these 
mice have severe neuronal migration defects resulting in a lissencephalic phenotype 
(Holzfeind et al., 2002; Lee et al., 2005; Michele et al., 2002). The only previously 
known human LARGE mutations (p.E509K and p.C667fs) were identified in a 
patient with CMD, subtle structural brain abnormalities and severe mental 
retardation (MDC1D). The less severe clinical phenotype of this patient could be 
explained by residual activity of the LARGE protein. By an overlay assay, the authors 
demonstrated that residual -dystroglycan present in a skeletal muscle biopsy in the 
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patient retained laminin- 2 binding, whereas this binding is lost in the myd mice 
(Holzfeind et al., 2002; Longman et al., 2003; Michele et al., 2002). 
The existence of phenotypic variability for different mutations is also reported for 
other WWS genes. Mutations in the POMT1/2 genes were initially identified in WWS 
(Beltrán-Valero de Bernabé et al., 2002; van Reeuwijk et al., 2005b), but 
subsequently also in milder conditions including limb-girdle muscular dystrophy 
subtype 2K (LGMD2K, MIM 609308) (Balci et al., 2005; Mercuri et al., 2006a; van 
Reeuwijk et al., 2006). Conversely, FKRP mutations are a common cause of LGMD, 
denoted subtype LGMD2I, but rare mutations are also found in severe conditions 
such as MEB and WWS, two similar disorders with CMD and severe brain and eye 
malformations (Beltrán-Valero de Bernabé et al., 2004; Brockington et al., 2001b). A 
common hypomorphic mutation in the FKTN gene causes FCMD in the Japanese 
population (Kobayashi et al., 1998). However, loss-of-function FKTN mutations are 
found in more severe conditions, including WWS (Beltrán-Valero de Bernabé et al., 
2003). Finally, different mutations in POMGnT1 cause phenotypic variability within 
the MEB disease spectrum (Taniguchi et al., 2003; Yoshida et al., 2001). 
LARGE is localized to the Golgi apparatus but the exact function of LARGE is 
unknown (Brockington et al., 2005; Grewal et al., 2005). It contains two putative 
catalytic domains, one related to a bacterial glycosyltransferase, and one related to a 
human glycosyltransferase (Grewal et al., 2001). In addition, LARGE interacts with 
the N-terminal domain of -dystroglycan, which is essential for normal glycosylation 
of this protein (Kanagawa et al., 2004). Another remarkable finding is the 
therapeutic potential of LARGE, demonstrated by the recovery of dystroglycan 
processing and functioning in WWS/MEB fibroblasts by overexpression of the 
LARGE gene (Barresi et al., 2004). 
Our finding demonstrates the existence of phenotypic variability, especially with 
regard to the brain, caused by different mutations in LARGE. We identified a 
mutation in this gene in 1 of 30 families, indicating that this gene is causal for only a 
small percentage of WWS patients. However, two spontaneous mouse mutants for 
Large, both due to intragenic deletions, have been reported in addition to the WWS 
patient described here (Grewal et al., 2001; Lee et al., 2005). The genomic size of 
LARGE may predispose this gene for genomic deletions. To exclude LARGE from 
genetic involvement in LGMD, or CMD with or without brain involvement it will be 
important to examine patients for genomic deletions in this gene. 
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Abstract 
The importance of O-glycosylation of -dystroglycan is evident from the 
identification of POMT1 mutations in Walker-Warburg syndrome. Approximately 
one-fifth of the Walker-Warburg syndrome patients show mutations in POMT1, 
which result in complete loss of protein mannosyltransferase activity. Walker-
Warburg syndrome patients are characterized by congenital muscular dystrophy 
with severe brain and eye abnormalities. This suggests a crucial role for 
-dystroglycan during development of these organs and tissues. Here we report new 
POMT1 mutations and polymorphisms in Walker-Warburg syndrome patients. In 
addition, we report different compound heterozygous POMT1 mutations in four 
unrelated families that result in a less severe phenotype than Walker-Warburg 
syndrome, characterized by congenital muscular dystrophy with calf hypertrophy, 
microcephaly, and mental retardation. Compared to Walker-Warburg syndrome 
patients, these patients have milder structural brain abnormalities, and eye 
abnormalities were absent, except for myopia in some cases. In these patients we 
postulate that one or both transcripts for POMT1 confer residual protein 
O-mannosyltransferase activity. Our data suggest the existence of a disease spectrum 
of congenital muscular dystrophy including brain and eye abnormalities resulting 
from POMT1 mutations. 
Introduction 
Extensive studies on yeast protein mannosyltransferases (Pmt)  showed that proper 
O-mannosylation of proteins is required for cell wall rigidity and cell integrity 
(Gentzsch and Tanner, 1996). Human protein O-mannosyltransferase 1 (POMT1; 
MIM#607423) is closely related to members of the yeast Pmt4 subfamily. POMT1 
O-mannosyltransferase activity appears to be necessary for the first step in 
O-glycosylation of -dystroglycan, which is transfer of a mannosyl residue from 
Dol-P-Man to Ser/Thr residues (Manya et al., 2003; Willer et al., 2003). 
Homozygous POMT1 mutations account for Walker-Warburg syndrome (WWS; 
MIM#236670) in nearly one-fifth of patients, and such patients typically have 
hypoglycosylation of -dystroglycan in affected muscle tissue (Beltrán-Valero de 
Bernabé et al., 2002). WWS patients rarely live beyond the first year of life because 
of multiorgan involvement. Patients have congenital muscular dystrophy (CMD), eye 
abnormalities such as cataract, microphthalmia, buphthalmia, and Peters anomaly, 
and severe structural brain defects. Brain defects include hydrocephalus, 
lissencephaly, agenesis of the corpus callosum, fusion of the hemispheres, cerebellar 
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hypoplasia, and neuronal overmigration, which causes a cobblestone cortex 
(Beltrán-Valero de Bernabé et al., 2002; Cormand et al., 2001; Dobyns et al., 1989; 
van Reeuwijk et al., 2005a). We have shown that mutations in POMT2 
(MIM#607439), FKTN (MIM#607440), and FKRP (MIM#606596) also give rise to 
WWS, in a small percentage of the patients (Beltrán-Valero de Bernabé et al., 2003; 
Beltrán-Valero de Bernabé et al., 2004; van Reeuwijk et al., 2005b). Muscle biopsies 
from these patients showed similar hypoglycosylation of -dystroglycan suggesting a 
common defective pathway. Other CMDs with brain involvement, like muscle-eye-
brain disease (MEB; MIM#253280), and Fukuyama congenital muscular dystrophy 
(FCMD; MIM#253800) reflect other genes involved in this glycosylation pathway 
and a genotype-phenotype correlation for those genes has been established or is 
likely to exist (Diesen et al., 2004; Kondo-Iida et al., 1999; Taniguchi et al., 2003; 
van Reeuwijk et al., 2005a). POMT1 mutations in WWS patients cause premature 
stop codons or create amino acid substitutions and deletions in conserved domains. 
This suggests that these mutations may reflect null alleles (Beltrán-Valero de 
Bernabé et al., 2002; Kim et al., 2004). In vitro experiments have demonstrated the 
disruptive effect of these mutations on the O-mannosyltransferase activity of POMT1 
(Akasaka-Manya et al., 2004). In this study we report the results of POMT1 mutation 
analysis in 28 WWS patients. In eight WWS cases we identified seven novel 
mutations and one previously described mutation. In addition, mutation analysis 
was performed in patients with a less severe phenotype, consisting of CMD with calf 
hypertrophy, microcephaly, and severe mental retardation. Causative compound 
heterozygous mutations were identified in four unrelated families. One family is of 
Dutch origin. Three families are of Italian origin, including two families that were 
described earlier (Villanova et al., 2000) and were subsequently labelled „„Italian 
MEB‟‟ (Muntoni et al., 2003), although eye abnormalities (severe myopia) were 
present in only a single patient. In this work, we refer to these four families as 
congenital muscular dystrophy plus mental retardation (CMD/MR). 
Patients, material, and methods 
Patients The clinical features as well as brain MRIs for Patients 1 and 2 (first 
cousins) and Patient 3 from Italian unrelated families are strikingly similar and were 
described previously (Villanova et al., 2000). In short, these patients have severe 
mental retardation, microcephaly, hypertrophy of the quadriceps and calf muscle, 
and structural brain abnormalities (Figure 1), but no eye abnormalities. Patients 1 
and 2 never developed the ability to walk and are presently 18 and 17 years old. 
Patient 3 died at the age of 3.5 years from bronchopneumonia due to swallowing 
problems and aspiration.  
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Figure 1. Cerebral MRIs of Patients 3 and 5, compared with a typical WWS patient. Sagittal fluid 
attenuation inversion recovery MRI (repetition time [TR]=512 msec/echo time [TE]=15 msec) showing 
hypoplasia of the corpus callosum, brainstem and cerebellum (A). Transverse relaxation time (T2) MRI 
(TR=3,475 msec/TE=150 msec) shows frontal atrophy and abnormal thickening of the frontal cortex 
(cortical dysplasia) in the typical WWS patient and in Patient 5, but normal cortex in Patient 3 (B). 
Arrows indicate the following abnormalities: occipital encephalocele (1); cerebellar hypoplasia (2); 
hypoplasia of the brainstem (3); hypoplasia of the corpus callosum (4); severe (supratentorial) 
hydrocephalus (5); abnormal thickening of the frontal cortex (cortical dysplasia) (6); no cortical 
abnormalities (7). 
 
Patient 4 is a 16-year-old girl of Italian descent born from non-consanguineous 
parents. She presented at birth, following a normal pregnancy and delivery at term, 
with hypotonia and microcephaly. Her developmental milestones were characterized 
by gross delay, with acquisition of the sitting posture at 16 months and inability to 
walk unsupported. Bilateral hip dislocation was noticed at 2 months and severe 
myopia at 9 months. The patient had severe mental retardation, was unable to 
speak, and displayed stereotypic hand-regard movements. Her serum creatine 
kinase (CK) was markedly elevated at 5,000 U/l (normal value is <200 U/l). 
Moderate hypertrophy of the thigh muscles was present. A brain MRI performed at 
the age of 2 years showed megacisterna magna and cerebellar hypoplasia and 
dilatation of the IV ventricle. The white matter signal was normal and no gross 
supratentorial cortical dysplasia was visible. At the age of 13 years her head 
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circumference was 46 cm (below -2.5 standard deviations [SD]); her sitting posture 
was characterized by mild scoliosis, and flexion contractures of her hips and knees, 
and equinovarus posture of her feet. A muscle biopsy performed at the age of 5 years 
was dystrophic with intact laminin- 2 staining. There was no further muscle tissue 
available to study -dystroglycan expression. 
Patient 5 is a Dutch boy from non-consanguineous parents, who recently died at the 
age of 4 years. At birth he was hypotonic and contractures were absent. At the age of 
4 months, severe visual impairment was suspected. Serum CK level was 6,125 U/l. 
Ultrasound imaging showed atrophy and increased echodensity of muscles. A muscle 
biopsy was refused. At the age of 6 months, after the cerebral MRI was done  
(Figure 1) a diagnosis of MEB was made. At the age of 4 years he was microcephalic 
with a head circumference of 45 cm (below -2.5 SD). Binocular visual acuity (Teller 
Acuity Cards) was 0.25. There was myopia, astigmatism, and bilateral optic nerve 
hypoplasia. Ocular pressure was normal, cataract was absent. He had a myopathic 
face with open mouth. Supine position was frog-like with generalized muscle 
atrophy, paucity of spontaneous movements, and severe hypotonia with absence of 
head balance. Flexion contractures of both knees and Achilles tendons were present. 
Sitting without support was not possible. Patients 6 to 13 are typical WWS patients. 
Table 1 gives an overview of the clinical features of the CMD/MR patients (Patients 
1 to 5) compared to WWS and MEB patients. Informed consent was obtained from 
all analyzed subjects. 
Linkage analysis DNA was extracted from blood lymphocytes using standard 
procedures. A genome-wide screening was performed in one family (Patients 1 and 
2) using a 400–microsatellite marker set (Applied Biosystems; 
www.appliedbiosystems.com) at the French National Centre of Genotyping (CNG; 
www.cng.fr). Linkage to the WWS locus was assessed by genotyping subjects for 
microsatellite markers flanking POMT1, D9S1863, D9S179, and the intragenic 
marker, D9S64, which is located in intron 2 of the POMT1 gene (Beltrán-Valero de 
Bernabé et al., 2002). PCR was carried out with 40 ng of DNA. We used the 
touchdown PCR method, with annealing temperature decreasing from 65 to 55°C in 
the first 10 cycles, and fixed at 55°C in the final 20 cycles. All PCRs were done using 
0.5 U Platinium Taq polymerase (Invitrogen; www.invitrogen.com) for amplification 
in a final volume of 15 µl. PCR products were amplified using forward primers 
labelled at their 5‟ end with 6-Fam or Hex fluorochromes, and migrated on an ABI 
377 automated sequencer. Data were analyzed by the Genscan (version 3.1) 
Genotyper 2.5 software (Applied Biosystems) and haplotypes were constructed. 
Mutation analysis Primer sequences, conditions for PCR amplification, and 
DNA sequencing of 19 coding exons of POMT1 (NM_007171.1) in all families was 
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performed as described previously (Beltrán-Valero de Bernabé et al., 2002). In the 
case of missense mutations, we determined their causative involvement by checking 
the Mendelian segregation in family members, and by excluding the presence of 
these mutations in at least 100 control chromosomes. 
 
Table 1. Clinical features of patients 1-5 (CMD/MR), compared to WWS and MEB patients 
Feature WWS* MEB* Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Brain        
Cortical abnormalities Y+++ Y++ Y+ Y+ N N Y++ 
Encephalocele Y N N N N N N 
Hydrocephalus Y+++ Y++ Y+ Y+ N N Y+ 
White matter 
abnormalities 
Y+++ Y+ Y+ Y+ Y+ N Y+ 
Fusion of hemispheres Y++ N N N Y+ N N 
Septum hypoplasia Y+++ Y++ N N N N Y+ 
Corpus callosum 
hypoplasia 
Y+++ Y+ N N N N Y+ 
Cerebellar cortex 
hypoplasia 
Y+++ Y++ Y+ Y++ Y Y Y+ 
Cerebellar vermis 
hypoplasia 
Y+++ Y++ Y+ Y+ Y+ Y Y+ 
Speech (words) N N Y+ Y+ Y+ N N 
Mental retardation Y+++ Y+++ Y++ Y++ Y++ Y++ Y++ 
Microcephaly N N -3 SD  -3 SD  -3 SD -2.5 SD -2.5 SD 
Eye        
Microphthalmia Y++ Y N N N N N 
Myopia Y Y N N Y++ Y Y 
Retinal dysplasia Y++ Y+ N N N N N 
Muscle        
Serum CK 
(normal value: 200 U/l) 
>5x >2x 20x 40x >10x >10x 30x 
Calf hypertrophy N N Y Y Y N (thigh) Y 
Macroglossia N N Y Y N ND ND 
Other        
Able to walk N N N N N N N 
Age (years) <3 <30 18 17 3.5, † 16 4.5, † 
*Clinical features of WWS and MEB patients as previously reported (Beltrán-Valero de Bernabé et al., 2002; Cormand et 
al., 2001; Taniguchi et al., 2003); Y, observed; N, not observed; +, mild; ++, moderate; +++, severe; ND, no data; CK, 
creatine kinase; †, deceased  
 
Amino acid conservation In order to determine amino acid conservation of 
POMT1 in multiple species we made a multiple alignment of human POMT1 
orthologous protein sequences using MUSCLE (Edgar, 2004). Proteins with the 
following GenBank accession numbers were included in the alignment: 
NP_009102.1 (Human); AAS76201.1 (Mouse); NP_445858.1 (Rat); 
NP_001025856.1 (Chicken); CAF89480.1 (Fish); AAH75534.1 (Frog); XP_318526.2 
(Mosquito); NP_524025.2 (Fly); and NP_596807.1, EAK86491.1, XP_460584.1, 
EAK95207.1, XP_451701.1, AAS50686.1, NP_012677.1, XP_449354.1, 
XP_503607.1, EAA64589.1, XP_332024.1, AAP05785.1, and EAA67633.1 (Fungi). A 
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Clustal colour scheme with a 10% conservation threshold was used to indicate 
conserved residues in the alignment (Clamp et al., 2004).  
Results 
Linkage analysis To unravel the genetic basis of two Italian families in which 
three affected individuals were diagnosed with CMD associated with severe mental 
retardation, structural brain abnormalities, and muscle hypertrophy, we undertook 
genome-wide linkage mapping on the most informative family with two patients. 
Although these patients are first cousins, born to non-consanguineous parents, we 
hypothesized that a founder mutation may be shared by this and other previously 
reported Italian families in which linkage to LAMA2 (MIM#156225), POMGnT1 
(MIM#606822), and FKTN was excluded (Villanova et al., 2000). After analyzing 
several potential loci, no common homozygous markers were found for Patients 1 to 
3 and additional patients originating from Italy with similar phenotypes. We then 
analyzed the genome-wide linkage data based on the hypothesis that Patients 1 and 2 
may carry the same compound heterozygous mutations. This allowed the 
identification of POMT1 as a candidate, since the two affected individuals shared 
identical haplotypes for intragenic and POMT1 flanking markers. Patient 3 appeared 
to have different haplotypes at the POMT1 locus (Figure S1). 
Mutation Analysis POMT1 mutation analysis was performed in two related 
(Patients 1 and 2) and 39 unrelated sporadic cases. Twenty-eight cases were 
diagnosed as WWS, seven cases as intermediate MEB/WWS, and seven cases as 
CMD including calf hypertrophy, microcephaly, and mental retardation. This last 
group includes the two Italian families described above (Figure S1) and four other 
families in which no linkage analysis was performed. Four out of these six families, 
including the two Italian families, revealed causative compound heterozygous 
mutations for POMT1 (Figure 2). In addition, we detected causative POMT1 
mutations in 7 out of 28 WWS cases. None of the missense mutations was detected 
in more than 100 chromosomes from control subjects. We found no causative 
mutations in seven cases of an intermediate MEB/WWS phenotype. All causative 
POMT1 mutations identified in this study are listed in Table 2. A schematic 
overview of all causative POMT1 mutations known to date is given in Figure 2. In 
addition to causative POMT1 mutations we identified three rare exonic 
polymorphisms and one intronic polymorphism that have not been described before. 
An overview of all exonic and rare intronic polymorphisms identified in affected 
individuals is given in Table 3. 
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Figure S1. Pedigrees of two Italian families showing haplotypes for chromosome 9q34 polymorphic 
markers and the segregating POMT1 mutations. Affected individuals are denoted by blackened symbols 
and unaffected individuals by unblackened symbols; the deceased family members are indicated by 
diagonal slashes. The haplotypes segregating with the disease phenotype are shown by black bars with 
the marker alleles. 
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Figure 2. Schematic representation of thePOMT1 protein including all mutations known to date. The 
highly conserved protein mannosyltransferase (PMT) domain is indicated by a light grey box. Another 
conserved region is indicated by three dark grey boxes where the mannosyl-IP3R-RyR (MIR) motifs are 
located. Both conserved elements are thought to be involved in the recognition and/or binding of protein 
substrates, and/or catalysis. Transmembranous, endoplasmic reticulum (ER), and cytoplasmic parts of 
the protein are indicated in black, gray, and light gray, respectively. Mutations resulting in WWS are 
given below the schematic representation of the POMT1 protein while mutations resulting in the milder 
phenotype are given on top, except for the mutation p.A200P between the asterisks that results in 
LGMD2K (Balci et al., 2005). Connecting lines between mutations indicate compound heterozygosity 
and homozygous mutation are in bold. Novel mutations are indicated by italic font. Changes in highly 
conserved (human-yeast) amino acids are underlined. 
 
Genotype-phenotype correlation for POMT1 mutations  
The expanding phenotype of POMT1 mutations is suggestive for a genotype-
phenotype correlation resulting from mutations that affect transcript or protein in 
different degrees of severity. We studied whether substituted or deleted amino acids 
were conserved across multiple species and looked further to see if these amino acids 
were located in an important domain or 2D structure of the protein. In order to 
determine the conservation of amino acids we made a multiple alignment of POMT1 
orthologous protein sequences from different species (Figure S2). The amino acid 
substitution of highly conserved amino acids (similar residue throughout the 
alignment) is underlined in Figure 2. It is remarkable that most mutations in WWS 
patients that result in amino acid substitution or deletion are located in the highly 
conserved PMT and MIR domains, although not all affected amino acids are highly 
conserved. The only exception is the S537R mutation (Currier et al., 2005). 
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Table 2. POMT1 sequence variants and amino acid changes    
Patient (Origin) Diagnosis Nucleotide variant Amino acid 
Amino acid 
conservation 
Domain 
2D 
structure 
1 & 2 (Italy) 
CMD/ 
MR 
c.193G>A 
c.1746G>C 
p.G65R 
p.W582C 
++ 
++++ 
PMT 
No 
Coil 
Coil 
3 (Italy) 
CMD/ 
MR 
c.1540C>T 
c.1770G>C 
p.R514X 
p.Q590H 
N.A. 
++++ 
3‟ MIR 
No 
Coil 
Strand  
4 (Italy) 
CMD/ 
MR 
c.418_420delATG 
c.2167dupG* 
p.M140del 
p.D723fs* 
+ 
N.A. 
PMT 
No 
Helix 
Coil 
5 (Netherlands) 
CMD/ 
MR 
c.1149-2A>G 
c.2174C>G 
(splice site) 
p.S725X 
N.A. 
N.A. 
MIR 
No 
Coil 
Coil 
6 (Netherlands) WWS 
c.427G>A 
c.1104delC 
p.E143K 
p.F369fs 
++ 
N.A. 
PMT 
MIR 
Helix 
Coil 
7 (Pakistan) WWS Hom. c.313C>T p.R105C ++++ PMT Helix 
8 & 9 (Lebanon) WWS Hom. c.314G>A p.R105H ++++ PMT Helix 
10 (India) WWS 
c.620G>T 
c.1332delG 
p.G207V 
p.W444X 
++++ 
N.A. 
PMT 
MIR 
Helix 
Strand 
11 (Qatar) WWS Hom. c.1456delT p.W486fs N.A. MIR Coil 
12 (Ireland) WWS Hom c.2167dupG* p.D723fs* N.A. No Coil 
13 (Turkey) WWS Hom. C.907C>T p.Q303X N.A. No Helix 
*The POMT1 (NM_007171.1) mutations p.Q303X and p.D723fs have previously been identified (p.D723fs 
as p.G722fs in compound heterozygosity with p.V428D) in WWS patients (Beltrán-Valero de Bernabé et 
al., 2002). Hom, homozygous, N.A., not applicable, Amino acid conservation of  human POMT1 (Figure 
S2) in mammals (+), birds, fish, frogs (++), insects (+++), yeast (++++), PMT, protein mannosyl 
transferase domain; MIR, Mannosyltransferase; IP3R and RyR domain 
 
 
Figure S2. Multiple sequence alignment of POMT1 orthologous protein sequences from different 
species illustrating the amino acid conservation at different positions in the POMT1 protein that are 
deleted or substituted as a result of mutations in POMT1 in WWS patients or in CMD/MR patients. 
Changes of highly conserved residues are underlined. 
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Table 3.  POMT1 polymorphisms 
Nucleotide variant 
Amino 
acid 
Amino acid 
conservation 
Domain 
2D 
structure 
Reference* 
c.718T>G p.C240G − PMT Helix rs4997217 
c.739A>G p.M247V − PMT Helix rs4995933 
c.751C>T p.R251W − PMT Coil rs3887873 
c.752G>A p.R251Q − PMT Coil rs2296949 
c.855G>C (1%) p.L285F ++ PMT Helix This study 
c.942C>T p.T314T +++ No Coil rs10901065 
c.979G>A p.V327I + MIR Strand rs4740164 
c.1113T>C p.D371D ++++ MIR Coil rs3739494 
c.1299C>A p.D433E +++ MIR Coil rs11243406 
c.1565G>A (1%) p.R522K − No Coil This study 
c.1758G>A p.R586R + No Coil Currier et al., 2005 
c.1922C>T p.A641V + No Helix rs12115566 
c.2097C>T (1%) p.S699S + No Helix This study 
c.1148+16G>A Intronic N.A. N.A. N.A. Balci et al., 2005 
c.1241+98_99delCT Intronic N.A. N.A. N.A. Balci et al., 2005 
c.1764+48G>C Intronic N.A. N.A. N.A. Balci et al., 2005 
c.1764+107A>C Intronic N.A. N.A. N.A. Balci et al., 2005 
c.1765-6_7CC>AA (3%) Intronic N.A. N.A. N.A. This study 
c.2069+13T>C Intronic N.A. N.A. N.A. Balci et al., 2005 
*Referenced in NCBI SNP Cluster Report. New polymorphisms in POMT1 (NM_007171.1) are shown in bold 
with their frequency in between brackets. The changes p.L285F and p.R522K were designated as rare 
polymorphisms as they were identified only in heterozygosity in consanguineous patients. In addition these 
are non-conserved residues, which are substituted by a residue that is also present at corresponding positions 
of orthologous POMT1 protein sequences. N.A., not applicable, amino acid conservation of human POMT1 
(Figure S3) in mammals (+), birds, fish, frogs (++), insects (+++), yeast (++++), no conservation (−), PMT, 
protein mannosyl transferase domain; MIR Mannosyltransferase; IP3R and RyR domain 
 
Figure S3. Multiple sequence alignment of POMT1 orthologous protein sequences from different species 
illustrating the amino acid conservation at different positions in the POMT1 protein. Novel polymorphic 
changes identified in WWS patients in this study are p.L285F, p.R522K, and p.S699S (silent mutation). 
Changes of highly conserved residues are underlined. 
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However, the causation of this S537R change is not proven, because this was the 
only heterozygous change identified in the POMT1 gene of a WWS patient. In 
addition, amino acid S537 is poorly conserved (Figure S2). In three patients 
affected with a milder CMD/MR phenotype (Patients 1, 2, and 4), we found an 
amino acid substitution (c.193G>A, p.G65R) and deletion (c.418_420delATG, 
p.M140del) in the PMT domain, but these changes did not involve highly conserved 
amino acids. 
Discussion 
Here we describe seven novel POMT1 mutations, in seven WWS patients that show 
typical WWS symptoms as described earlier (Cormand et al., 2001; Dobyns et al., 
1989). In total we identified POMT1 mutations in approximately one-fifth of the 
WWS patients in our cohort, including the patients for which the POMT1 locus was 
excluded by haplotype analysis. This is consistent with our previous study, but 
different from a recent report in which it was shown that the incidence of POMT1 
mutations in WWS patients can be as low as 7% (Currier et al., 2005). 
The POMT1 mutations in WWS patients that are known to date are predicted to be 
highly disruptive toward the mannosyltransferase activity of the protein, because in 
nearly all cases they predict truncated proteins or amino acid substitution, or 
deletion, at critical positions. Indeed, almost complete loss of POMT1 activity has 
been established for some of the WWS missense mutations (Akasaka-Manya et al., 
2004). We therefore postulated that mild mutations in POMT1 give rise to a milder 
phenotype than WWS. Haplotype analysis in two unrelated Italian families with 
three CMD/MR patients (Patients 1, 2, and 3) identified POMT1 as a candidate gene. 
Mutation analysis by direct sequencing of POMT1 in these patients with a less severe 
phenotype revealed compound heterozygous mutations (c.193G>A, p.G65R; 
c.1746G>C, p.W582C and c.1540C>T, p.R514X; c.1770G>C, p.Q590H). Direct 
sequencing of POMT1 in two more patients, from Italian (Patient 4) and Dutch 
(Patient 5) origin, with similar clinical features also revealed compound 
heterozygous mutations (c.418_420delATG, p.M140del; c.2167dupG, p.D723fs and 
c.1149–2A>G; c.2174C>G, p.S725X, respectively). If our hypothesis is correct then 
one or both mutations in these CMD/MR patients should be relatively mild, i.e., 
leading to a mutant POMT1 protein with residual activity. Indeed, the amino acid 
substitutions and deletions identified in these patients either affect nonconserved 
residues (p.G65R and p.M140del) or affect amino acids that are located outside the 
recognizable protein motifs (p.W582C and Q590H). One of the CMD/MR patients 
(Patient 5) is compound heterozygous for a splice-site mutation (c.1149–2A>G) and 
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a nonsense mutation (c.2174C>G) in the last exon. Although these appear to be 
severe mutations, this is not necessarily the case. For example, there are several 
alternative splice sites close to position c.1149, which would give rise to transcripts in 
which the reading frame is maintained. Also, the S725X nonsense mutation is the 
most C-terminal truncation known to date and may yield a protein with residual 
enzymatic activity. Additional experiments are required to determine the actual 
effects of the POMT1 mutations, such as measurement of protein 
O-mannosyltransferase activity in patient cell lines or in transfected cell systems 
(Akasaka-Manya et al., 2004). Unfortunately, no cell lines are available for the 
patients described here. 
The existence of POMT1 mutations that result in a relatively mild phenotype is 
suggestive for a genotype-phenotype correlation for POMT1 mutations as pointed 
out previously for other causative genes (i.e., FKTN) for WWS and other congenital 
muscular dystrophies with brain involvement (Diesen et al., 2004; Kondo-Iida et al., 
1999; Taniguchi et al., 2003; van Reeuwijk et al., 2005a). Mild POMT1 mutations 
may result in even milder disorders of O-glycosylation, as recently reported for a 
homozygous founder missense mutation (c.598G>C, p.A200P) in five Turkish 
patients with autosomal recessive limb girdle muscular dystrophy (LGMD2K;  
#MIM 609308) and mild mental retardation (Balci et al., 2005). 
Two recent publications demonstrate the simultaneous requirement of POMT1 as 
well as POMT2 to obtain protein mannosyltransferase activity in human and in 
Drosophila (Ichimiya et al., 2004; Manya et al., 2004). We recently reported POMT2 
mutations in three WWS patients (van Reeuwijk et al., 2005b). This suggests that 
mild mutations in POMT2 may also give rise to a mild phenotype. 
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Abstract 
Dystroglycanopathies are a heterogeneous group of disorders caused by defects in 
the glycosylation pathway of -dystroglycan. The clinical spectrum ranges from 
severe congenital muscular dystrophy with structural brain and eye involvement to a 
relatively mild adult onset limb-girdle muscular dystrophy without brain 
abnormalities and normal intelligence. Mutations have been identified in one of six 
putative or demonstrated glycosyltransferases. Many different mutations have been 
identified in FKRP, which cover the complete spectrum of dystroglycanopathies. In 
contrast to the other known genes involved in these disorders, genotype-phenotype 
correlations are not obvious for FKRP mutations. To date no homozygous or 
compound heterozygous null mutations have been identified in FKRP, suggesting 
that null mutations in FKRP could result in embryonic lethality. We report a family 
with two siblings carrying a homozygous mutation in the start codon of FKRP that is 
likely to abolish FKRP protein function. The clinical phenotype of the patients was 
consistent with Walker-Warburg syndrome, the most severe disorder in the disease 
spectrum of dystroglycanopathies. 
Introduction 
Defective O-linked glycosylation of the peripheral membrane protein -dystroglycan 
is the common pathophysiological mechanism in a group of disorders, referred to as 
dystroglycanopathies. The clinical phenotypes range from adult onset limb-girdle 
muscular dystrophy (LGMD2I, MIM 607155) to early lethal Walker-Warburg 
syndrome (WWS, MIM 236670). WWS is characterized by a combination of 
congenital muscular dystrophy (CMD), and structural brain and eye abnormalities 
(Brockington et al., 2001b; van Reeuwijk et al., 2005a). A specific type of 
glycosylation, O-linked mannose glycosylation is a prerequisite for binding of 
-dystroglycan to ligands such as laminin- 2, agrin, and perlecan in muscle, and 
neurexin in the brain. The only known target for this type of glycosylation is 
-dystroglycan, and together with other proteins of the dystrophin-glycoprotein 
complex it forms a link between extracellular matrix proteins and the actin 
cytoskeleton (Barresi and Campbell, 2006). Mutations have been reported in six 
putative or demonstrated glycosyltransferases; FKRP, FKTN, LARGE, POMGnT1, 
POMT1, and POMT2. Initially, each gene was associated with one of the syndromes; 
FKRP mutations giving rise to MDC1C, FKTN mutations in FCMD patients, a 
LARGE mutations in a patient with MDC1D, POMGnT1 mutations in MEB patients, 
and POMT1 and POMT2 mutations in WWS patients (Beltrán-Valero de Bernabé et 
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al., 2002; Brockington et al., 2001a; Kobayashi et al., 1998; Longman et al., 2003; 
van Reeuwijk et al., 2005b; Yoshida et al., 2001). However, mutation analysis in 
patients with milder or more severe syndromes within the dystroglycanopathy 
spectrum demonstrated clinical variability for different mutations in each of the 
dystroglycanopathy genes (Godfrey et al., 2007). A wide clinical spectrum is most 
evident for FKRP mutations that were first reported in patients with MDC1C (MIM 
606612), subsequently in patients with the milder LGMD2I, and later also in 
patients with CMD and mild structural brain involvement, in muscle-eye-brain 
disease (MEB, MIM 253280) and in WWS patients with severe structural brain and 
eye involvement (Beltrán-Valero de Bernabé et al., 2004; Brockington et al., 2001a; 
Brockington et al., 2001b; Mercuri et al., 2006b; Topaloglu et al., 2003). Mutations 
have been identified throughout the FKRP coding sequence 
(http://www.dmd.nl/fkrp_seqvar.html). Most mutations result in amino acid 
substitutions, and few mutations result in a premature termination codon in 
compound heterozygosity with an amino acid substitution. A genotype-phenotype 
correlation is not obvious for most of these mutations of which the functional 
consequences are hard to predict owing to a lack of knowledge about the function of 
the FKRP protein (Mercuri et al., 2006b; van Reeuwijk et al., 2005a). There is some 
evidence that the degree of loss of high molecular weight -dystroglycan, detected by 
immunocytochemistry and Western blot analysis in MDC1C and LGMD2 patients, 
correlates with the clinical severity (Brown et al., 2004; Mercuri et al., 2003; 
Mercuri et al., 2006b). Also patients with Fukuyama congenital muscular dystrophy 
(FCMD, MIM 253800), MEB, or WWS caused by mutations in one of the other 
genes produce a hypoglycosylated form of -dystroglycan which is less capable of 
binding to laminin- 2 (Kim et al., 2004; Michele et al., 2002). 
Recently a patient with MDC1C was reported to carry a homozygous FKRP stop 
codon mutation, c.1378C>T, Gln460X (Mercuri et al., 2006b). Our group previously 
reported a homozygous missense mutation (c.953G>A, Cys318Tyr) in a patient with 
WWS, which is clinically the most severe case reported with FKRP mutations. Based 
on these observations, and the absence of evident loss-of-function mutations in 
FKRP, it was hypothesized that FKRP null mutations are not compatible with life 
(Beltrán-Valero de Bernabé et al., 2004; de Paula et al., 2003; Mercuri et al., 2003; 
Mercuri et al., 2006b). Here we report a WWS family with two siblings carrying a 
homozygous start codon mutation in FKRP, which most likely results in loss of 
FKRP protein function. 
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Patients and methods 
Patient 1 The oldest affected sibling, the first child of consanguineous 
Caucasian parents was born at 37+1 weeks after an elective Caesarean section. At 34 
weeks of gestational age severe hydrocephalus was diagnosed by ultrasonography, 
performed because of diminished moving of the child. The Apgar scores were 6 and 7 
after 3 and 5 minutes, respectively. Examination after birth revealed a 
macrocephalic boy with a birth weight of 2930 gram and a head circumference of 43 
cm (>>+2SD). The anterior fontanel was large and bulging with palpable separation 
of the cranial sutures. The pupils were asymmetric (right 3 mm, left 2 mm) with 
bilateral absent pupillary reflexes to light. He showed limited spontaneous limb 
movements mainly of the arms. Tendon reflexes were all hard to elicit. He had no 
sucking reflex, grasping was present in the hands but absent in both feet. At 
ophthalmologic examination the right eye appeared to be smaller (cornea diameter 
OD 8 mm, OS 10 mm). Blood vessels in the iris were dilated. There was bilateral 
cataract, more pronounced in the right eye. Fundi and intraocular vessels appeared 
to be normal.  
Postnatal brain MRI (Figure 1) showed extreme enlargement of the lateral 
ventricles and the 3rd ventricle with a small malformed 4th ventricle suggestive of 
aqueduct stenosis. Although interpretation of the cortex was difficult due to severe 
hydrocephalus, there seemed to be decreased cortical gyration with a cobblestone 
aspect. Both cerebellar hemispheres, the vermis and the pons were small with 
abnormal kinking position of the brainstem. The MRI confirmed microphthalmia 
and revealed persistent hyperplastic primary vitreous of the right eye. 
Spine radiography showed no abnormalities. Neonatal hearing screening was 
abnormal. Serum creatine kinase could not be measured due to a limited blood 
sample. A muscle biopsy from the quadriceps muscle showed a dystrophic pattern 
with atrophic and hypertrophic muscle fibers, extensive necrosis of fibers and 
increase of central nuclei. Immunohistochemistry showed reduced staining of 
dystrophin 1 with normal staining of sarcoglycans and merosin. Postnatal 
chromosomal analysis revealed a 46, XY karyotype.  
It was decided not to perform neurosurgical intervention and the child died at the 
age of 6 days due to respiratory failure. Consent was not given for autopsy. 
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Figure 1. Cerebral MRI of patient 1. A: Sagittal T1 showing severe hydrocephalus, hypoplastic brainstem 
and cerebellar vermis (arrows), and absent corpus callosum. B: Axial T2 showing cobblestone 
lissencephaly and enlarged ventricles. 
 
Patient 2 In the younger affected sibling, severe hydrocephalus was diagnosed 
at 17+5 weeks of gestation (Figure 2). Chromosomal analysis after amniocentesis 
revealed a normal 46, XX karyotype. At 23+3 weeks of gestation she was born dead 
after birth induction. Her birth weight was 530 gram. No visible eye abnormalities 
were seen. Consent was not given for autopsy. 
The combination of abnormalities of brain, eye and muscle in patient 1 was 
indicative for a dystroglycanopathy. Differentiating between MEB and WWS is 
difficult due to significant clinical overlap. However, MEB patients are 
predominantly diagnosed in the Finnish population and mostly die after early 
childhood (Cormand et al., 2001). Most WWS patients die in their first year of life 
(Dobyns et al., 1989). The clinical phenotype of patient 1, showing extreme prenatal 
hydrocephalus, severe brain malformation with neuronal migration defect, presence 
of severe eye abnormalities with microphtalmia and cataract, congenital muscular 
dystrophy, and the early lethal course is consistent with a diagnosis of WWS 
(Cormand et al., 2001). The younger female sibling was diagnosed with prenatal 
hydrocephalus, suggestive for the same diagnosis. 
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Figure 2. Ultrasound examination of patient 2 at 17+5 weeks 
of gestation showing severe hydrocephalus. 
 
 
Genetic analysis DNA was extracted from peripheral blood lymphocytes 
using standard methods. 10K SNP-array analysis (GeneChip® Mapping 10K 2.0 
Array, Affymetrix, USA) was carried out at our linkage facility. Regions ≥10 cM or 
with ≥20 consecutive homozygous SNPs, and identical genotypes for both affected 
siblings were defined as regions of homozygosity. Mutation analysis for FKRP was 
performed as described previously (Beltrán-Valero de Bernabé et al., 2004). 
Results 
The affected siblings were born to consanguineous parents. In order to map the 
disease causing mutations, we performed genome-wide homozygosity mapping by 
10K SNP-array analysis. We identified a homozygous region of 66 contiguous SNP 
markers on chromosome 19 with identical genotypes in both affected siblings 
(Figure 3). This region of 33 cM in size encompasses the FKRP locus. By direct 
sequencing of the FKRP coding DNA we identified a homozygous mutation in the 
start codon (c.1A>G, Met1Val) in both affected siblings. Both parents were 
heterozygous carriers of this mutation.  
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Figure 3. 10K SNP-array analysis identified 10 regions of homozygosity (>=10 cM or 
with >=20 consecutive homozygous SNPs) with identical genotypes for both affected 
siblings. The FKRP locus resides in the largest region of 33 cM and 66 homozygous 
SNPs on chromosome 19. 
 
Discussion 
Mutations in the FKRP, FKTN, LARGE, POMT1, and POMT2 genes are associated 
with WWS. The genetic cause for the majority of WWS patients remains unknown. 
FKRP is one of the six known genes (including POMGnT1) in which mutations result 
in defective glycosylation of -dystroglycan (Brockington et al., 2001a). FKRP 
mutations have been reported to cause a broad spectrum of clinically related 
muscular dystrophies with severe neurological impairment at the severe end of the 
spectrum. FKRP-associated disorders include LGMD2I,  MDC1C, CMD with mild 
structural brain involvement, MEB, and WWS (Brockington et al., 2001a; 
Brockington et al., 2001b; Mercuri et al., 2006b; Topaloglu et al., 2003). 
Immunocytochemical labeling and Western blot analysis of muscle biopsies from 
these patients with antibodies that recognize the O-glycan moiety of -dystroglycan 
(VIA4-1, IIH6) show a variable reduction of -dystroglycan labeling, which suggests 
an association between the reduced labeling and the clinical presentation resulting 
from FKRP mutations (Brown et al., 2004; Mercuri et al., 2003; Mercuri et al., 
2006b).  
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Figure 4. Schematic representation of the FKRP protein and the phenotype associated 
with different mutations in FKRP. A: the coding DNA sequence of the FKRP gene is 
contained in one exon. The homozygous Met1Val mutation, identified in a WWS family in 
this study is shown in bold. Use of an in frame alternative translational start site (Met143) 
will result in loss of the N-terminal part of the FKRP protein including the signal peptide 
(SP), which is important for its targeting to the Golgi (Esapa et al., 2002). LicD (Pfam 
domain PF04991) is found in protein involved in phosphorylcholine metabolism. B: 
different mutations in homozygosity or compound heterozygosity give rise to a range of 
dystroglycanopathies as described in further detail in the main text.  
 
One of the most common Mendelian mutations in any gene is the FKRP missense 
mutation, c.826C>A (Leu276Ile). The mutation is of European origin, but is found in 
patients throughout the world (Bushby and Beckmann, 2003). In homozygous state 
this mutation causes the mildest phenotype observed for FKRP mutations, a relative 
mild form of late-onset  LGMD without visible neurological or eye involvement 
(LGMD2I). Patients who are compound heterozygous for the Leu276Ile mutation 
show either a slightly more severe LGMD phenotype or even early onset muscular 
dystrophy (Figure 4). Hence, these „partner‟ mutations with Leu276Ile are 
suggested to be more detrimental for FKRP function than the Leu276Ile (Beltrán-
Valero de Bernabé et al., 2004; Mercuri et al., 2003). Indeed, the c.919T>A 
(Tyr307Asn) mutation together with Leu276Ile results in a patient with a severe 
LGMD2I phenotype who died in his late teens. The severe effect of the Tyr307Asn 
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mutation was confirmed by its homozygosity in a MEB patient. Likewise, two 
patients carrying the Leu276Ile mutation in compound heterozygosity with the start 
codon mutation Met1Val caused a similar severe LGMD2I phenotype as for the 
Tyr307Asn/Leu276Ile combination (Mercuri et al., 2003; Quijano-Roy et al., 2006). 
Hence, it is not surprising that a homozygous mutation Met1Val was associated with 
the severe WWS phenotype in two patients from the WWS family presented here. 
This start codon mutation may result in the use of an alternative start codon 
downstream of the coding sequence. The next two potential translational start sites 
are out of frame. The first alternative in frame translational start site is located 143 
codons downstream of the original start codon, and will result in loss of N-terminal 
residues important for Golgi targeting and retention of the FKRP protein (Esapa et 
al., 2002). The homozygous Met1Val mutation identified is this study is likely to 
abolish the FKRP protein function and represents the severe end of the clinical 
spectrum associated with FKRP mutations.  
The only other FKRP mutation associated with WWS predicts an amino acid 
substitution Cys318Tyr. The evolutionary conserved cysteine residue appears to be 
required to form disulphide bridges for protein folding, which are crucial for the 
function of FKRP. Only one homozygous nonsense mutation, c.1378C>T (Gln460X), 
has been reported for a patient with MDC1C (Mercuri et al., 2006b), suggesting that 
this homozygous nonsense mutation is not as severe as the FKRP mutations 
identified in MEB and WWS patients. This may be explained by residual activity of 
the corresponding mutant FKRP protein, which lacks the last 36 amino acids. 
Clearly, the Met1Val and Cys318Tyr mutations are more disruptive and likely 
represent null-alleles. Hence, null mutations in FKRP and other genes involved in 
the O-linked glycosylation of -dystroglycan such as FKTN, POMT1, POMT2 and 
LARGE, appear to be associated with the most severe end of the dystroglycanopathy 
spectrum, WWS. Only for POMGnT1, null alleles are associated with a slightly 
milder phenotype, MEB. 
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Introduction 
The term “dystroglycanopathies” recently emerged in the literature to denote a 
growing group of clinically related disorders that result from disruption of the 
binding of -dystroglycan to extracellular ligands. No mutations have been found in 
-dystroglycan itself and hypoglycosylation of this protein is the only known 
pathogenic feature common to these disorders. To date, recessive mutations have 
been identified in six different genes in a variety of clinically distinct 
dystroglycanopathies. Reported clinical phenotypes range from adult-onset 
limb-girdle muscular dystrophy (LGMD2I) to early lethal congenital muscular 
dystrophy with severe structural brain-, and eye abnormalities (Walker-Warburg 
syndrome [WWS]). 
In this chapter I will discuss the implications of the identification of two new WWS 
genes reported in this thesis, and the clinical spectrum caused by these and other 
known dystroglycanopathy genes. In addition I will discuss our current diagnostic 
approach for WWS and related disorders, and future prospects for the identification 
of new WWS genes. 
WWS genetics 
Previous studies identified mutations in three WWS genes, POMT1, FKRP, and 
FKTN, in approximately one-fifth of the WWS patients in our cohort (Beltrán-Valero 
de Bernabé et al., 2002; Beltrán-Valero de Bernabé et al., 2003; Beltrán-Valero de 
Bernabé et al., 2004). The molecular explanation for a majority of WWS patients 
remained elusive and genome-wide homozygosity mapping in consanguineous 
families suggested further genetic heterogeneity (Chapter 2). 
In order to identify new WWS loci we performed (genome-wide) homozygosity 
mapping in additional WWS patients, followed by a candidate-gene-approach. This 
resulted in the identification of two new WWS genes, POMT2, and LARGE (Chapters 
3 and 4). We considered POMT2 as a candidate gene for WWS because the 
involvement of its paralog POMT1 in WWS, and their overlap in expression pattern. 
In addition, RNAi knockdown of POMT1 or POMT2 in Drosophila shows a striking 
phenotypic similarity, and both proteins act in concert to obtain 
O-mannosyltransferase activity in Drosophila as well as in human (Ichimiya et al., 
2004; Manya et al., 2004). We identified three homozygous POMT2 mutations in 
three out of 41 WWS families (7%) (Chapter 3). A previous study by our group failed 
to identify POMT2 mutations in a cohort 30 patients, in which six patients (20%) 
carried a POMT1 mutation (Beltrán-Valero de Bernabé et al., 2002). A French study 
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confirmed this lower frequency of POMT2 mutations (7%), compared to POMT1 
mutations (32%) in a cohort of 47 fetal cases of type 2 lissencephaly (Bouchet et al., 
2007). In contrast, another study of 30 WWS patients reveals that the frequency of 
POMT1 mutations can also be as low as 7% (Currier et al., 2005). It is not clear why 
we and others find a difference in mutation frequencies between POMT1 and 
POMT2. Both proteins are similar in structure and function, and are both together 
required to obtain O-mannosyltransferase activity. Also, common mutations cannot 
explain the difference. 
We considered LARGE as a candidate gene for WWS as a defect in the mouse Large 
gene is known to cause the myd (myodystrophy) mouse phenotype (Grewal et al., 
2001). Myd mice have a short life span and show abnormalities very similar to WWS 
with involvement of muscle, eye, and brain, including lissencephaly. We performed 
homozygosity mapping of the LARGE locus in 30 WWS families, followed by 
mutation analysis in the six families that linked to this region. In one WWS family 
with two affected siblings we identified a homozygous intragenic 63-kb deletion 
(Chapter 4). Like the two deletions found in spontaneous mouse mutants for Large 
(Grewal et al., 2001; Lee et al., 2005) this deletion disrupts the open reading frame 
of LARGE, most likely resulting in a loss of LARGE protein function. An earlier study 
demonstrated the involvement of LARGE compound heterozygous mutations 
(p.E509K, p.C667fs), in a patient with a milder form of congenital muscular 
dystrophy, subtle brain abnormalities and mental retardation (MDC1D) (Longman 
et al., 2003). Several functional studies show the importance of the LARGE protein 
for O-linked glycosylation of -dystroglycan. LARGE contains two putative catalytic 
glycosyltransferase domains, and an interaction of LARGE with the N-terminal 
domain of -dystroglycan is required for normal glycosylation of this protein. 
However, the exact function of this Golgi-resident protein remains unknown 
(Brockington et al., 2005; Grewal et al., 2001; Grewal et al., 2005; Kanagawa et al., 
2004). LARGE may be involved in the synthesis of sugar chains other than the 
O-mannosyl sugar chains identified on -dystroglycan. One of the putative catalytic 
domains of LARGE is similar to N-acetylglucosaminyltransferase and lectin-binding 
analyses indicate the presence of terminal -linked GlcNAc (Combs and Ervasti, 
2005). This hypothesis is supported by the observations that overexpression of 
LARGE generates highly glycosylated -dystroglycan even in cells from WWS and 
MEB patients who have defects in synthesis of O-mannosyl sugar chains, which is 
not observed by overexpression of i.e. POMGnT1 and FKRP (Barresi et al., 2004; 
Esapa et al., 2002). 
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Figure 1. Diagram of 
genetic causes of WWS. 
Mutations in FKRP (2), 
FKTN (3), LARGE (1), 
POMT1 (17), and 
POMT2 (4) are 
responsible for WWS 
in approximately one-
third (27/84) of the 
patients from our 
research cohort 
 
Mutations in the two new WWS genes, POMT2, and LARGE, and mutations 
identified in the three previously identified genes, POMT1, FKRP, and FKTN, 
together account for approximately one-third of the WWS patients from our cohort 
(Figure 1). Genome-wide homozygosity mapping data from 27 genetically unsolved 
WWS families provides evidence for extensive genetic heterogeneity (see below). 
Clinical spectrum and genotype-phenotype correlations 
Mutations in the six genes encoding putative or demonstrated glycosyltransferases, 
FKRP, FKTN, LARGE, POMGnT1, POMT1, and POMT2, are associated with a broad 
clinical spectrum (Figure 2), which is much wider than previously envisaged. 
Within the group of dystroglycanopathies, phenotypic diversity not only occurs for 
different mutated genes but also for different mutations within each of the genes. 
Initially mutations in POMT1, and POMT2 were identified in patients with WWS. 
Recent work by our group and by others showed that mutations in these genes may 
also give rise to less severe disorders (Chapter 5) (Balci et al., 2005; Biancheri et al., 
2007; D'Amico et al., 2006; Godfrey et al., 2007; Mercuri et al., 2006a; Yanagisawa 
et al., 2007). Conversely, mutations in FKRP, FKTN, and LARGE, may cause WWS 
while mutations in these genes were previously identified in clinically less severe 
disorders (Chapters 4 & 6) (Beltrán-Valero de Bernabé et al., 2003; Beltrán-Valero 
de Bernabé et al., 2004; Godfrey et al., 2007; Silan et al., 2003). 
Mutations identified in POMGnT1 show the least phenotypic diversity. Most patients 
manifest a phenotype consistent with muscle-eye-brain disease (MEB). Some 
variability regarding the brain abnormalities can be noted in some cases, which can 
be milder or more severe, resembling those seen in FCMD or WWS patients, 
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respectively (Taniguchi et al., 2003). The only notable exception is a case report of a 
patient with LGMD and normal intellect, carrying a homozygous missense mutation 
(p.Asp556Asn) in POMGnT1 (Clement et al., 2008). A report of a Turkish family 
provides a strong case for intrafamiliar clinical variability for MEB. Two siblings 
carrying the same homozygous splice-site mutation in POMGnT1, resulting in a 
deletion of 42 amino acids, show a remarkable difference in severity of the MEB 
phenotype, suggesting that the phenotype is prone to modification by genetic or 
environmental factors (Teber et al., 2008). Given the extreme broad clinical 
spectrum for each of the six known genes, it is impossible to assign the genetic defect 
to a specific gene, solely on the basis of the clinical characteristics of an individual 
patient. 
 
 
 
Figure 2. Overview of published mutations (in numbers) in the dystroglycanopathy genes and 
associated phenotypes ranging from relatively mild limb-girdle muscular dystrophy to severe Walker-
Warburg syndrome. Abbreviations: LGMD, limb-girdle muscular dystrophy; MR, mental retardation; 
CMD, congenital muscular dystrophy; CRB, cerebellar involvement; FCMD, Fukuyama CMD, MEB, 
muscle-eye-brain disease; WWS, Walker-Warburg syndrome. 
 
Correlations between the predicted effect of a mutation on the protein function, and 
the resulting clinical features, also referred to as a genotype-phenotype correlation 
can be observed for some mutations. This is most evident for Walker-Warburg 
syndrome where nearly all mutations were predicted to completely abolish protein 
function. These mutations predict either a truncated transcript, or frameshift in the 
open reading frame, or amino acid substitution or deletion at critical positions of the 
protein (this Thesis) (Godfrey et al., 2007). Less evident is a genotype-phenotype 
correlation for POMGnT1 mutations. Some of the mutations in POMGnT1 that are 
predicted to be highly disruptive also show a more severe MEB phenotype, which 
closely resembles a WWS phenotype (van Reeuwijk et al., unpublished data) (Hehr 
et al., 2007; Taniguchi et al., 2003; Teber et al., 2008). In contrast, a recent study 
could not establish a genotype-phenotype correlation for the wider MEB disease 
spectrum based on POMGnT1 enzyme activity measurements in vitro and in muscle 
biopsies of patients with novel POMGnT1 mutations (Hehr et al., 2007). They show 
that truncating and missense mutations throughout POMGnT1 uniformly result in 
complete loss of POMGnT1 enzyme activity, and also report that there is no obvious 
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correlation between the location of the mutation and the severity of the cerebral 
malformations, as was reported in a previous study (Taniguchi et al., 2003). 
Interestingly, the clinically mildest POMGnT1 mutation known to date, 
p.Asp556Asn, does show POMGnT1 activity although the kinetics of POMGnT1 
activity in the patients‟ fibroblasts differs from that of control fibroblasts. This 
residual POMGnT1 activity likely results in the milder phenotype of the patient with 
LGMD and normal intellect (Clement et al., 2008). 
Mutations in POMGnT1, POMT1 and POMT2 are often associated with the severe 
end of the spectrum of dystroglycanopathies, such as MEB and WWS, whereas FKRP 
has a higher contribution to the milder end of the clinical spectrum, such as MDC1C 
and LGMD2I. Multiple factors may play a role in this phenomenon, such as the 
specific function or step that is disrupted in the catalysis of the O-linked mannosyl 
glycans onto -dystroglycan or functional redundancy of the mutated protein. Also 
founder mutations play an important role in this phenomenon. One example is 
MEB, which is one of the Finnish heritage disorders. Almost all Finnish MEB 
patients carry the same (homozygous) splice-site mutation (c.1539+1G>A) in 
POMGnT1 (Diesen et al., 2004). In Japan, FCMD is the second most common 
genetic disorder due to a founder mutation in the 3‟ UTR of FKTN (Kobayashi et al., 
1998). This mutation has also been observed in Korea, where it may have originated 
prior to the invasion of Japan from the mainland more than 2000 years ago or more 
recently from a migrant from Japan to Korea (Colombo et al., 2000; Watanabe et al., 
2005). Finally, the Leu276Ile mutation in FKRP is a very common mutation in 
northern Europe with a frequency of 1 in 200 alleles in the Danish and United 
Kingdom population, and 1 in 600 in the German population (Brockington et al., 
2001b; Sveen et al., 2006; Walter et al., 2004). The mutation is of European origin 
and is found in patients with a mild form of LGMD2I throughout the world. The 
commonality of this mutation may partly be explained by genetic drift, or an 
unknown selection pressure to maintain this mutation, or both (Bushby and 
Beckmann, 2003; Frosk et al., 2005). 
WWS diagnostics and genetic counseling 
The presence of genetic heterogeneity in WWS and related disorders complicates 
diagnostic studies and genetic counseling. Mutation analysis is available in a 
diagnostic setting for all known dystroglycanopathy genes; FKRP, FKTN, LARGE, 
POMGnT1, POMT1, and POMT2 (www.dnadiagnostieknijmegen.nl). When parental 
consanguinity is known or suspected, a prescreen is conducted with genetic markers 
located in or nearby these genes. Based on homozygosity for these markers, the six 
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genes may be prioritized prior to laborious mutation analysis. Recently, enzymatic 
assays have been developed to test enzyme activities of POMGnT1, POMT1, and 
POMT2 in patient lymphoblast cell lines. If these cell lines are available, these assays 
provide a noninvasive, and inexpensive method, which can be undertaken prior to 
mutation analysis (Manya et al., 2008; Vajsar et al., 2006). Hypoglycosylation of 
-dystroglycan in muscle biopsies of dystroglycanopathy patients is shown by a 
reduced immuno-labeling of -dystroglycan with antibodies to glyco-epitopes of 
-dystroglycan (VIA4-1, IIH6) compared to the immuno-labeling with core protein 
antibodies (GT20ADG). A challenging task remains to identify a serum glycoprotein 
which is also hypoglycosylated in dystroglycanopathy patients, which would enable a 
less invasive screening method for dystroglycanopathies. Another possibility for 
future diagnostics may be the grouping of dystroglycanopathy gene defects based on 
hypoglycosylation profiles of the molecular mass of -dystroglycan in patients‟ 
lymphoblast or fibroblast cell lines. The major drawback of the diagnostic methods 
discussed here is their small success rate, since the majority of patients do not carry 
mutations in any of the six known genes. Figure 3 shows a scheme for the 
diagnostic procedure that I propose for (suspected) dystroglycanopathy patients.  
Together with the identification of new WWS genes, new methods for mutation 
analysis need to be developed to facilitate diagnostic testing of multiple genes. Rapid 
developments in sequencing technologies may facilitate specific sequencing of WWS 
genes in a more time and cost efficient manner (Albert et al., 2007; Hodges et al., 
2007; Okou et al., 2007; Porreca et al., 2007). Second generation sequencing 
technologies, such as Roche-454 (www.454.com), Illumina-Solexa 
(www.illumina.com), and ABI-SOLiD (www.appliedbiosystems.com), facilitate 
sequencing of up to gigabase amounts in a single run. However, these high-
throughput technologies still require enrichment of target sequences and extensive 
bioinformatic analysis, which presently precludes their practical application in a 
diagnostic setting.  
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Figure 3. Proposal workflow gene sequencing of dystroglycanopathies based on mutation 
frequencies for the different clinical categories. Clinical categories are defined as described 
previously (Godfrey et al., 2007). Abbreviations: WWS, Walker-Warburg syndrome; MEB, 
muscle-eye-brain disease; LGMD, limb-girdle muscular dystrophy; CMD, congenital muscular 
dystrophy; CRB, cerebellar involvement; MR, mental retardation. *prescreen with genetic 
markers in or surrounding the six genes for initial exclusion of genes for mutation analysis based 
on heterozygosity. 
 
Unravelling the unknown genetic causes of WWS 
With the identification of mutations in six genes involved in WWS and related 
disorders we and others obtained more insight into the etiology of these disorders. 
The pathomechanism shared by these disorders is disruption of the synthesis of 
O-linked mannose glycans found on -dystroglycan (Figure 4). However, 
homozygosity mapping, direct mutation analysis or both excluded the involvement 
of the six known dystroglycanopathy genes in a majority of the WWS patients in our 
research cohort. Based on our genome-wide homozygosity mapping data from 27 
families we predict the existence of several other WWS loci (see below). This implies 
the involvement of several other crucial components in the O-mannosylation 
pathway of -dystroglycan. We performed homozygosity mapping, direct mutation 
analysis or both in our research cohort for obvious candidates from this pathway 
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such as the gene encoding dystroglycan (DAG1), and the genes encoding 
1,4-galactosyltransferases (B4GALT1-B4GALT7) and -2,3-sialyltransferases 
(ST3GAL1-ST3GALT6) that catalyse the addition of  galactosyl and 
N-acetylneuraminic acid, respectively, to the major O-linked oligosaccharide found 
on -dystroglycan, Neu5Ac( 2-3)Gal(ß1-4)GlcNAc(ß1-2)Man( 1)-Ser/Thr. Although 
the results were negative for these genes, we cannot exclude their involvement in 
dystroglycanopathies. Similar as for POMT2 it is possible that more patients need to 
be tested before disease causing mutation are identified. In any case, these genes will 
not have an important contribution to the prevalence of WWS.  
 
 
Figure 4. Glycosylation of -dystroglycan. Localization of glycosyltransferases involved in the O-
glycosylation pathway of -dystroglycan within the cellular organelles. Known steps of the 
glycosylation pathway are represented on the left. 
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Identification of the genetic factors for unsolved WWS patients remains challenging. 
Nearly all patients display large regions of homozygosity as their parents are in most 
cases first cousins. Siblings share only a quarter of these regions on average, 
therefore homozygosity mapping in affected siblings can considerably reduce the 
number of homozygous candidate disease loci within a family. Most of the WWS 
families in our research cohort involve 
a single case of WWS (Table 1).  
The power of homozygosity mapping to 
resolve the genetic cause for rare 
autosomal recessive disorders largely 
depends on a homozygous candidate 
disease locus on the genome that is 
shared by affected individuals from 
different consanguineous families or 
shared by all affected kindred from a 
single consanguineous family with 
multiple affected individuals 
(Chapter 1). However, due to the large 
extent of genetic heterogeneity for WWS it is not possible to exclude homozygous 
candidate disease loci that are not shared between patients from different families, 
resulting in many regions of homozygosity. In addition, the small number of WWS 
families with more than one affected sibling further limits the application of 
homozygosity mapping for WWS. No LOD scores above 3 can be obtained in such 
families, which is a measure for statistical significance for a genetic localisation. 
Nonetheless, we performed LOD score analysis for all 27 families as a method to 
quantify the homozygous regions across the genome that are shared by these 
families. Totals of positive LOD scores for all families were calculated and plotted for 
each chromosome (Figure 5). 
  
Table 1. WWS research cohort (57 families*) 
Affected single cases: 48 
two siblings: 7 
three siblings: 2 
Diagnosis WWS: 38 
WWS-MEB-like: 19 
Consanguinity 32 
Mapping data 10K: 13 
250K: 14 
*Including only patient for which DNA is available 
for research; 10K, Affymetrix GeneChip® Mapping 
10K 2.0 Array; 250K, Affymetrix Nsp array from 
the GeneChip® Human Mapping 500K Array set 
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Figure 5. Overview of homozygous regions on all autosomal chromosomes for 27 WWS(-like) families. 
The sum of the LOD scores (vertical) is plotted for each SNP markers by genetic position (horizontal). 
Patients DNA samples were genotyped for SNP markers using the 10K or 250K GeneChip® Mapping 
arrays. Regions of homozygosity across the genome were determined by parametric multipoint LOD 
score analysis using the program easyLINKAGE with the Allegro algorithm (Hoffmann and Lindner, 
2005). The sum of the LOD scores per marker were calculated and plotted. Black stars indicate nine 
regions of homozygosity as listed in Table 3 
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The majority of the patients from our cohort are born to first cousin parents. The 
maximum LOD score for patients from first cousin parents is 1.2 for single cases 
(21), 1.8 for two siblings (4), and 2.4 for three siblings (2). This maximum LOD score 
has been used to determine regions of homozygosity by descent. By adding up the 
LOD scores for all families, the maximum of the sum of LOD scores for a one-locus 
hypothesis is 37.2. The maximum sum of the LOD scores that we obtained is 9.3 at 
three chromosomal regions, 1q44, 5q14.1, and 12q21.2-21.31. These LOD scores do 
not reach the maximum sum of the LOD scores for a one-locus hypothesis by far, 
which strongly supports further genetic heterogeneity. Based on the genome-wide 
homozygosity data presented in Figure 5, I have attempted to determine the 
minimum number of additional WWS loci. It appeared that at least nine different 
non-overlapping chromosomal segments are required to cover the homozygous 
regions of all 27 families that were analyzed (Table 2). Patients from all 27 families 
are homozygous for at least one of these nine loci and therefore these nine regions 
may contain all mutations that cause WWS in these families. 
 
Table 2. Overview of regions of homozygosity for 27 WWS(-like) families. Patients from the 27 
families are homozygous for at least one of these nine loci.  
 Families 
Chr Chr band 
Sum 
LOD 
Size 
(cM) Size (bp) 
UCSC 
genes 4 21 25 26 28 31 32 37 43 53 56 76 79 80 81 83 84 102 104 107 111 112 113 117 122 124 128 
1 q44 9,4 4,7 2,5E+06 26  0.5  1,2 0,5   1,2  1,2     1,2    1,1  1,2  0,5  0,8   
1 q24.1-24.2 7,3 2,0 7,8E+05 7    1,2 1,2     1,2  1,2   0,2       1,2     1,1 
1 q31.1 8,0 0,8 1,8E+06 0    0,9      1,2  1,2 1,2    1,1    1,2     1,2  
5 q14.1 9,2 1,4 1,2E+06 10  0,9          0,8 1,2 1,2     1,8   1,2 1,2  0,9   
11 q13.1-13.2 5,5 8,6 3,7E+06 87    0,4 1,2 2,5     0,8   0,1  0,3       0,2     
12 q21.2-21.31 9,4 2,0 2,0E+06 10 1,2        1,2  1,6     1,8 1,2 1,2    1,2      
13 q31.1-31.3 7,3 2,7 6,1E+06 4   2,4  1,2   0,1      1,2      1,2   1,2     
15 q21.3-22.2 8,2 6,5 3,9E+06 22 1,2   1,2 1,1     1,2    1,2    1,2      1,1    
20 q13.13-13.2 3,6 7,9 3,4E+06 14       1,8    1,8                 
*Regions of homozygosity that are shared by most families (highest sum of the LOD scores) were 
selected. Next we selected those loci that are shared by families which are not contained in the other 
regions (families 25, 32, 107, 128). Grey boxes indicate the positive LOD scores for one of the 27 
families for one of the selected regions. LOD scores were calculated as described in Figure 4. 
 
Obviously, the most interesting candidate disease loci are those shared by most 
patients, represented by the highest sum of the LOD scores. However, these loci may 
include many genes, and mutation analysis by direct sequencing is still a laborious, 
costly, and time-demanding task. Prior to mutation analysis, we followed a 
candidate-gene-approach to select for genes predicted to functionally overlap with 
the products of one of more known WWS genes. The selection was based on 
properties of known WWS genes such as spatial and temporal expression, and on 
(predicted) properties of the encoded protein products, such as their possible role in 
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protein glycosylation. For disease loci containing a large number of genes, disease 
gene prioritization has been carried out by bioinformatic analysis using tools such as 
listed in Table 2 in Chapter 1. Yet, mutation analysis in a selection of candidate genes 
did not result in the identification of a new WWS gene (Table 3). 
 
Table 3. WWS candidate genes analysed by direct mutations analysis.  
WWS candidate locus WWS candidate gene(s) 
Mutation analysis 
(# of families) 
3p21.31 GMPPB, DAG1 10 
5p14.4-1p4.1 CDH9, CDH10, CDH12 3 
11q13.2 B3GNT1 3 
13q31.1-q31.3 
AF339814, GPC5, GPC6, 
NDFIP2, microRNAs, 
POU4F1, RBM26, SLITRK1, 
SLITRK5, SLITRK6, SPRY2 
4 
17q25.3 P4HB 20 
18q12.1-q12.2 GALNT1, B4GALT6 4 
 
 
In our experience, homozygosity mapping in small families, for a condition with an 
unexpected high degree of genetic heterogeneity has met with limited success. The 
recent application of high-density SNP-arrays now enables the detection of small 
regions of homozygosity, containing few genes. The detection of such small regions 
and the reduction in cost for high density SNP-array analysis has enabled inclusion 
of individuals with remote consanguinity or without pedigree information, who 
nevertheless show evidence of consanguinity by an excess of homozygosity. These 
SNP-arrays can also detect microdeletions or duplications in homozygous intervals, 
which would immediately identify the causative gene. For example, the intragenic 
LARGE deletion (Chapter 4) would have been uncovered by application of the 250K 
SNP-array. For large regions of homozygosity containing many genes, I suggest a 
systematic analysis of genes for a functional link to the O-mannosylation pathway by 
a concert of bioinformatic analysis tools as is recently described for the prioritization 
of candidate genes for type 2 diabetes and obesity (Tiffin et al., 2006). Also filtering 
of genes in the homozygous regions for their presence in relevant large-scale 
datasets such as the secretory pathway proteome can be successful as demonstrated 
with the identification of the gene causing impaired glycosylation in patients with 
cutis laxa (Gilchrist et al., 2006; Kornak et al., 2008). Furthermore, I suggest using 
complementing approaches to homozygosity mapping if possible, such as genome-
wide expression analysis to detect differences in expression levels resulting from 
mutations in new WWS genes. Another possibility is to perform RNAi targeting of 
genes in regions selected by homozygosity mapping in fibroblast cell lines, which are 
then screened for hypoglycosylation of -dystroglycan. However, next generation 
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sequencing technologies, as described above, may soon enable affordable large-scale 
sequencing of genomic regions selected by homozygosity mapping, which obviates 
the need of selection of candidate genes. 
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Summary 
The research described in this thesis was focused on the elucidation of genetic 
factors involved in Walker-Warburg syndrome (WWS). WWS is one of the many rare 
disorders caused by defects in protein glycosylation. Immunohistochemistry in 
muscle from WWS patients shows a defect in the O-linked glycosylation of 
-dystroglycan. Specific O-mannosyl glycans are crucial for the function of 
dystroglycan and hypoglycosylation results in a loss of binding of extracellular 
ligands, such as laminin- 2. Consistent with other disorders showing an autosomal 
recessive pattern of inheritance, the incidence of WWS is higher in populations with 
a high rate of consanguineous unions. This phenomenon was exploited to identify 
candidate loci by a specific method of linkage analysis, homozygosity mapping 
(Chapter 1).  
Prior to the work described in this thesis, autosomal recessive mutations were 
reported in three genes, FKRP, FKTN, and POMT1, in approximately one-fifth of the 
WWS patients in our research cohort (reviewed in Chapter 2). We performed 
homozygosity mapping in WWS patients, from consanguineous pedigrees and 
without mutations in these three genes. Next we performed mutation analysis for 
genes within the critical regions, that code for proteins with a possible role in 
O-linked glycosylation of dystroglycan. This resulted in the identification of 
mutations in two new WWS genes, POMT2, and LARGE. We identified POMT2 
mutations in three of six families showing homozygosity at the POMT2 locus 
(Chapter 3). Immunohistochemistry in muscle showed markedly reduced levels of 
glycosylated -dystroglycan, which is consistent with the requirement of an active 
enzyme complex of POMT1 and POMT2 to obtain O-mannosyl transferase activity. 
Despite the common structural and functional characteristics of POMT1 and 
POMT2, we and others detected a lower mutation frequency for POMT2 in WWS 
and related disorders. 
A spontaneous deletion of Large in mice is associated with a severe neuromuscular 
phenotype that resembles WWS-like disorders. We identified a 63-kb intragenic 
deletion in the LARGE gene in one of the six WWS families homozygous at the 
LARGE locus by copy number analysis and direct sequencing, thereby describing the 
fifth WWS gene (Chapter 4).  
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Mutations in the six genes that encode for putative or demonstrated 
glycosyltransferases, FKRP, FKTN, LARGE, POMGnT1, POMT1, and POMT2, give 
rise to a range of dystroglycanopathies with a much wider spectrum of clinical 
manifestations than previously described (Chapter 7). Within the group of 
dystroglycanopathies, phenotypic diversity not only occurs for different mutated 
genes but also for different mutations within each of the genes. Consequently, it is 
currently not possible to predict the involvement of a specific gene, solely on the 
basis of the phenotype. A correlation between the predicted effect of a mutation on 
the protein function, and the resulting clinical phenotype, also referred to as a 
genotype-phenotype correlation, can however be observed for some mutations in 
specific genes within the O-linked glycosylation pathway. This is most evident for 
WWS where nearly all mutations are predicted to completely abolish protein 
function. We identified POMT1 null mutations in WWS patients and compound 
heterozygous POMT1 mutations in a group of patients with a relatively mild 
condition of congenital muscular dystrophy and mental retardation (Chapter 5). 
The majority of known FKRP mutations result in amino acid changes causing a 
limb-girdle muscular dystrophy or a relatively mild congenital muscular dystrophy. 
However, we identified a homozygous FKRP start codon mutation in two WWS 
siblings, suggesting that null mutations in FKRP result in the severe WWS 
 (Chapter 6). The mutations we identified in WWS patients in POMT2 
 (Chapter 3) and LARGE (Chapter 4) are likely to abolish the corresponding 
protein functions. Likewise, truncating mutations within the FKTN gene are 
associated with WWS. Less phenotypic diversity is seen for POMGnT1 mutations, 
where most mutations give rise to muscle-eye-brain disease. 
We have described the genetic cause for WWS in approximately one-third of the 
patients in our research cohort by the identification of mutations in FKTN, FKRP, 
LARGE, POMT1, and POMT2. We predict the existence of at least nine other WWS 
loci based on our genome-wide homozygosity data from 27 additional WWS families 
(Chapter 7). This suggests an unexpectedly high degree of  genetic heterogeneity 
for this rare but clinically recognizable syndrome, and underscores the complexity of 
the glycosylation machinery for -dystroglycan. Finding additional causative genes 
for WWS will shed more light on processes involved in O-linked glycosylation of 
-dystroglycan and may provide clues for new candidate genes for WWS. The nine 
additional loci selected by homozygosity mapping in 27 WWS families contain at 
least 180 genes. Candidate disease gene prioritization will be necessary to select 
genes for mutation analysis by direct sequencing in this valuable cohort. Next 
generation high-throughput sequencing technologies may soon enable sequencing of 
the complete homozygous genomic regions in these patients, which will obviate the 
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often difficult task of candidate gene selection. Given the presence of genetic 
heterogeneity, high-throughput sequencing will also be desirable for DNA-diagnostic 
analysis of WWS, when all underlying genes have been identified. 
 
Samenvatting 
Het in dit proefschrift beschreven onderzoek was gericht op het ontrafelen van de 
genetische factoren die het Walker-Warburg syndroom (WWS) kunnen veroorzaken. 
WWS is één van de vele zeldzame aandoeningen die veroorzaakt worden door 
defecten in de eiwitglycosylering. Immunohistochemie in spierweefsel van WWS 
patiënten toont een defect in de O-gebonden glycosylering van het eiwit 
dystroglycaan. Specifieke O-mannosyl glycanen zijn cruciaal voor de functie van 
dit eiwit en hypoglycosylering resulteert in een verlies van binding van extracellulaire 
liganden, zoals laminine 2. WWS patiënten worden gekenmerkt door ernstige 
aangeboren hersen- en oogafwijkingen en spierdystrofie. De incidentie van WWS is, 
overeenkomstig met andere autosomaal recessieve aandoeningen, hoger in 
bevolkingsgroepen met een hoog aantal consanguïne verbintenissen. Dit fenomeen is 
benut om kandidaatloci te identificeren middels een specifieke methode van 
koppelingsonderzoek, “homozygosity mapping” (Hoofdstuk 1). 
Voorafgaand aan het in dit proefschrift beschreven onderzoek werden bij ongeveer 
een vijfde van de WWS patiënten uit ons onderzoekscohort autosomaal recessieve 
mutaties beschreven in drie genen, FKRP, FKTN, en POMT1 (Hoofdstuk 2). Voor 
WWS patiënten met consanguïne ouders en zonder mutaties in deze drie genen werd 
homozygosity mapping uitgevoerd. Vervolgens werd mutatieanalyse uitgevoerd voor 
genen uit homozygote regio‟s die coderen voor eiwitten die mogelijk een rol spelen in 
de O-gebonden glycosylering van dystroglycaan. Dit heeft geresulteerd in de 
identificatie van twee nieuwe WWS genen, POMT2 en LARGE. POMT2 mutaties 
werden geïdentificeerd in drie van de zes families die homozygoot waren voor het 
POMT2 locus (Hoofdstuk 3). In spierweefsel werden duidelijk gereduceerde 
niveaus van geglycosyleerd dystroglycaan aangetoond met immunohistochemie, 
wat overeenkomt met een vereist actief enzym complex van POMT1 en POMT2 voor 
O-mannosyl transferase activiteit. Hoewel POMT1 en POMT2 structureel en 
functioneel veel overeenkomsten vertonen, hebben wij en anderen een lagere 
mutatie frequentie voor POMT2 in WWS en gerelateerde ziekten gevonden.  
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Een de novo deletie van Large in muizen veroorzaakt een ernstig neuromusculair 
fenotype dat vergelijkbaar is met WWS-achtige ziekten. In één van de zes WWS 
families die homozygoot waren voor het LARGE locus hebben we  een 63-kb 
intragene deletie in het LARGE gen gevonden door DNA kopieaantal analyse en 
DNA-sequentie analyse. Door dit resultaat zijn thans vijf WWS genen opgehelderd 
(Hoofdstuk 4). 
Mutaties in zes genen, die coderen voor veronderstelde of bewezen 
glycosyltransferases, FRKP, FKTN, LARGE, POMGnT1, POMT1 en POMT2, 
resulteren in een reeks van dystroglycaanaandoeningen met een veel breder 
spectrum van klinische verschijnselen dan voorheen was beschreven 
(Hoofdstuk 7). Fenotypische diversiteit binnen de groep van dystroglycaan-
aandoeningen is niet alleen het resultaat van verschillende gemuteerde genen, maar 
ook van verschillende mutaties in elk van de genen. Als gevolg hiervan is het 
momenteel niet mogelijk om de betrokkenheid van een bepaald gen uitsluitend aan 
de hand van het fenotype te voorspellen. Voor sommige mutaties in specifieke genen 
die betrokken zijn bij de O-gebonden glycosyleringsroute zien we echter wel een 
correlatie tussen het voorspelde effect van een mutatie op eiwitfunctie en het 
resulterende fenotype. Dit wordt ook wel een genotype-fenotype correlatie genoemd. 
Deze correlatie is het meest duidelijk voor WWS, waarbij voor de meeste mutaties 
wordt voorspeld dat ze de eiwitfunctie tenietdoen. In POMT1 hebben we met name 
homozygote nul mutaties geïdentificeerd in WWS patiënten, terwijl heterozygote 
POMT1 mutaties werden gevonden in een groep patiënten met een relatief milde 
aandoening van aangeboren spierdystrofie en mentale retardatie (Hoofdstuk 5). 
De meerderheid van de bekende FKRP mutaties resulteert in 
aminozuurveranderingen en veroorzaken limb-girdle spierdystrofie, een 
spieraandoening die zich pas op een latere leeftijd manifesteert, of relatief milde 
vormen van aangeboren spierdystrofie. Wij hebben echter een homozygote FKRP 
startcodon mutatie gevonden in twee WWS patiënten uit één familie, wat suggereert 
dat nul mutaties in FKRP resulteren in het ernstige WWS (Hoofdstuk 6). De in 
WWS patiënten geïdentificeerde mutaties in POMT2 (Hoofdstuk 3) en LARGE 
(Hoofdstuk 4) zijn hoogstwaarschijnlijk ook destructief voor de corresponderende 
eiwitfuncties. Hetzelfde geldt voor stopmutaties in het FKTN gen die geassocieerd 
zijn met WWS. Voor POMGnT1 is een genotype-fenotype correlatie minder duidelijk 
en zijn de meeste mutaties geassocieerd met muscle-eye-brain disease. 
Door de identificatie van mutaties in FKTN, FKRP, POMT1 en POMT2 hebben we 
voor ongeveer een derde van alle patiënten uit ons onderzoekscohort de genetische 
oorzaak van WWS beschreven. Op basis van de analyse van onze genoomwijde 
homozygosity mapping data van 27 additionele WWS families voorspellen we het 
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bestaan van tenminste negen andere WWS loci (Hoofdstuk 7). Dit suggereert een 
onverwacht hoge mate van genetische heterogeniteit voor dit zeldzame maar klinisch 
herkenbare syndroom, en onderstreept de complexiteit van het 
glycosyleringsmechanisme voor -dystroglycaan. Het vinden van nieuwe 
oorzakelijke WWS genen geeft mogelijk inzicht in tot nu toe onbekende processen 
betrokken bij O-gebonden glycosylering van -dystroglycaan. De negen loci, 
geselecteerd met behulp van homozygosity mapping in 27 WWS families, bevatten 
minstens 180 genen. Het prioriteren van kandidaatgenen zal noodzakelijk zijn voor 
de selectie van genen voor DNA-sequentie analyse. Nieuwe high-throughput 
sequentietechnologieën maken het binnenkort wellicht mogelijk om complete 
homozygote gebieden in deze patiënten te sequencen wat de moeilijke taak van 
kandidaatgenselectie zal ondervangen. Gegeven de genetische heterogeniteit voor 
WWS is high-throughput sequencen ook wenselijk voor WWS DNA-diagnostiek 
analyse wanneer alle onderliggende genen zijn geïdentificeerd. 
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erfelijke blindheid. 
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Dankwoord 
Het schrijven van dit proefschrift en het in dit proefschrift beschreven onderzoek is het 
resultaat van samenwerken, zowel professioneel, als privé. Daarom heel veel dank aan 
iedereen die op enige wijze hierbij betrokken is geweest. Er zijn een aantal mensen 
waarvoor ik mijn dank graag wil toelichten.   
 Hans van Bokhoven Beste Hans, als co-promotor ben jij het meest direct bij mijn 
werk betrokken geweest. Jouw passie en “gevoel” voor het onderzoek vind ik 
bewonderenswaardig, ook al is dat laatste soms moeilijk te doorgronden. Je hebt  mij als 
“grazer” leren “graven” en samen met Han heb je mij ook kritisch leren lezen en 
schrijven. Veel dank hiervoor en voor al die keren dat je voor mij de tijd hebt genomen 
wanneer ik bij je binnen liep terwijl je druk aan het worstelen was met het beantwoorden 
van die oneindige aanwas van e-mails. 
 Han Brunner Beste Han, jouw scherpe, directe en doortastende vragen schrikte mij in 
het begin soms af. Nu overheerst een gevoel dat ik juist voor dat soort vragen vaker met 
jou als promotor om de tafel had moeten gaan zitten. Ik heb enorm veel bewondering 
voor jouw kwaliteiten zoals ik die van jou als hoogleraar, wetenschapper, klinisch 
geneticus en afdelingshoofd ken. Ik hoop nog veel van je te kunnen leren. 
Christa van den Elzen Beste Christa, bedankt voor de prettige samenwerking, en de 
belangrijke bijdrage die je hebt geleverd aan het in dit proefschrift beschreven werk. 
Martijn Janssen Kerel, het was heel prettig samenwerken met jou als 
onderzoeksassistent.  Het voelde echt als “ons” project waarin ook jij je 
verantwoordelijkheid nam toen ik tijdelijk bij het CMBI werkte. Ik vond het heel jammer, 
maar begrijpelijk dat je vertrok richting Oss voor een vaste baan. Veel dank voor je inzet 
voor het onderzoek en voor je relaxte gezelligheid. 
Daniel Beltrán Dear Daniel, first a big thank you for your willingness to come over to 
Nijmegen to take part in the PhD examination committee, I feel really honored. You put 
Nijmegen on the map for research into the genetic causes of Walker-Warburg syndrome 
(WWS) by identification of the first three WWS genes. It was a big advantage for me to 
work with you at the beginning of my PhD studies. With Spanish passion you introduced 
me into WWS research, learned me a lot of practical tricks in the lab, and left me with 
many ideas and experiments to continue with. Muchas gracias, amigo. 
Tony Roscioli Dear Tony, I‟ll continue in Dutch because I am sure that you will be able 
to read Dutch very well by now with such a “talenknobbel”, as we say in Dutch. Ik ben blij 
dat jij het WWS onderzoek voortzet en ik twijfel er niet aan dat je binnenkort een nieuw 
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WWS gen zult vinden en het genetische mysterie rondom WWS verder zult ontraadselen. 
Heel veel dank ook voor het kritisch lezen van mijn thesis en voor jouw input voor ons 
FKRP manuscript. 
Martijn Huynen Beste Martijn, bedankt voor de mogelijkheid om in jouw groep 
bioinformatica-onderzoek te doen. Ik heb er erg veel van geleerd wat een belangrijke 
basis heeft gelegd voor mijn huidige werkzaamheden. Ik hoop nog veel met je te mogen 
samenwerken. 
Martin Oti Martin, bedankt voor al je hulp als ik weer eens met mijn handen in 
mijn haar zat hoe verder te gaan met een Python-, Perl- of een Shell-script. Jij hebt het 
“coconut” project voortgezet wat ons uiteindelijk een mooi artikel heeft opgeleverd. Heel 
veel dank hiervoor en voor je interesse in mijn onderzoek. 
Dorien Lugtenberg   Dorien, ondanks dat je het XLMR project voor mijn neus wegkaapte 
zijn we vanaf het begin maatjes geweest en hebben we heel wat aio-lief en leed met elkaar 
kunnen delen. Ik vond het heel leuk om jouw paranimf te zijn en ben ook blij dat jij de 
mijne wilt zijn. Ik kijk uit naar de tijd dat we er “ééntje” kunnen drinken op onze dr.  
Antropogenetica (ex-)collegae Beste allen, dank voor jullie behulpzaamheid en voor 
de gezelligheid op de werkvloer en tijdens de vele uitstapjes. Het is enorm motiverend 
om op een afdeling te werken waar wetenschappelijk onderzoek en patiëntenzorg zo 
dicht bij elkaar liggen, en waar, ondanks het grote aantal medewerkers, de afdeling voelt 
als één groot team.     
Jan Grijpstra Jan, ook jij kent de klappen van de aio-zweep! Tof dat jij mijn paranimf 
bent. Na onze Numico- en studietijd in Wageningen zijn we beiden aan dit avontuur 
begonnen, helaas niet aan dezelfde Universiteit wat de kwantiteit van discussies met een 
biertje erbij geen goed heeft gedaan. Als de promotie-hectiek voor ons beiden achter de 
rug is gaan we dit wat mij betreft weer vaker doen. Dank voor je vriendschap en voor alle 
optredens met je band Autumn waar ik keer op keer enorm van genoten heb. 
Ouders Lieve pa en ma, jullie onvoorwaardelijke steun en liefde heeft mij in staat gesteld 
dit persoonlijke succes te bereiken. Dank hiervoor en voor jullie betrokkenheid. Best leuk 
toch,  als we een dr. van Reeuwijk in de familie hebben?! 
Zus en Remko Dank voor de gezelligheid bij jullie thuis met mijn neefjes Sjors en Teis, 
en nichtje Zowi. Dit gaf mij de nodige afleiding en relativering van mijn werk. 
Schoonfamilie Lieve Cobi en Dick, Esther en Dennis, dank voor jullie interesse in mijn 
werk en de gezellige etentjes met elkaar. Het doet mij altijd goed met jullie en met 
nichtjes Ninke en Elze te zijn.   
Marsha Lief, het afgelopen jaar was best intensief voor ons beiden waardoor we minder 
quality time voor elkaar hebben gehad. Dank voor je begrip, steun, al je hulp, en je liefde. 
Ik hou van je.
  
  
 
